

Adjuvant Pembrolizumab versus Placebo in Resected St

New England Journal of Medicine

378, 1789-1801

DOI: [10.1056/nejmoa1802357](https://doi.org/10.1056/nejmoa1802357)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Perioperative Therapy in Renal Cell Carcinoma: What Do We Know, What Have We Learned, What's Next?. <i>Journal of Clinical Oncology</i> , 2018, 36, 3608-3614.	0.8	5
2	The 46th David A. Karnofsky Memorial Award Lecture: Oligometastasis—From Conception to Treatment. <i>Journal of Clinical Oncology</i> , 2018, 36, 3240-3250.	0.8	49
3	Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600E Mutant Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 3441-3449.	0.8	226
4	Tumors of the Nail Apparatus and Adjacent Tissues. , 2018, , 675-824.		2
5	Recent Developments in Gene Therapy and Immunotherapy. <i>Journal of Nanomedicine & Biotherapeutic Discovery</i> , 2018, 08, .	0.6	0
6	Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade. <i>Clinical and Translational Medicine</i> , 2018, 7, 32.	1.7	29
8	The forgotten role of adjuvant immune checkpoint inhibitors in preventing melanoma brain metastasis. <i>Immunotherapy</i> , 2018, 10, 1289-1291.	1.0	2
9	Efficacy and safety of PD-1 inhibitors for treating advanced melanoma: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2018, 10, 1293-1302.	1.0	14
10	Is earlier better for melanoma checkpoint blockade?. <i>Nature Medicine</i> , 2018, 24, 1645-1648.	15.2	28
11	Risk Factors for Regional and Systemic Metastases in Patients with Sentinel Lymph Node-negative Melanoma. <i>Anticancer Research</i> , 2018, 38, 6571-6577.	0.5	4
12	Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1. <i>Acta Dermato-Venereologica</i> , 2018, 99, 107-108.	0.6	2
14	Incidence of Placebo Adverse Events in Randomized Clinical Trials of Targeted and Immunotherapy Cancer Drugs in the Adjuvant Setting. <i>JAMA Network Open</i> , 2018, 1, e185617.	2.8	23
15	Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?. <i>Lancet Oncology</i> , The, 2018, 19, e720-e725.	5.1	25
16	Transformation of Old Concepts for a New Era of Cancer Immunotherapy: Cytokine Therapy and Cancer Vaccines as Combination Partners of PD1/PD-L1 Inhibitors. <i>Current Oncology Reports</i> , 2018, 20, 1.	1.8	30
17	Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. <i>Nature Medicine</i> , 2018, 24, 1649-1654.	15.2	592
18	Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: A retrospective study. <i>Journal of Hepatology</i> , 2018, 69, 1396-1397.	1.8	41
19	Neoadjuvant ipilimumab (3Âmg/kg or 10Âmg/kg) and high dose IFN-Î±2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire. , 2018, 6, 112.		50
21	Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time. <i>Frontiers in Immunology</i> , 2018, 9, 2265.	2.2	107

#	ARTICLE	IF	CITATIONS
22	Long-term survival with anti-PD-1-based immunotherapy, but what is the best approach?. <i>Lancet Oncology, The</i> , 2018, 19, 1424-1426.	5.1	1
23	Omitting Completion Dissection in Melanoma? Help is Available for Surgeons Coping Without Routine Dissection, But More Work is Needed. <i>Annals of Surgical Oncology</i> , 2018, 25, 3416-3418.	0.7	3
24	Eighth American Joint Committee on Cancer (AJCC) melanoma classification: what about stage IIC?. <i>British Journal of Dermatology</i> , 2018, 179, 1422-1423.	1.4	7
25	Selecting immuno-oncologyâ€‘based drug combinations â€‘ what should we be considering?. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 971-985.	1.3	5
26	Melanoma. <i>Lancet, The</i> , 2018, 392, 971-984.	6.3	1,016
27	Pembrolizumab for the first-line treatment of non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 1015-1021.	1.4	18
28	Multidisciplinary treatment strategies in high-risk resectable melanoma: Role of adjuvant and neoadjuvant therapy. <i>Cancer Treatment Reviews</i> , 2018, 70, 144-153.	3.4	27
29	Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy. <i>Cureus</i> , 2018, 10, e3700.	0.2	25
30	The new era of adjuvant therapies for melanoma. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 535-536.	12.5	73
31	Cutaneous melanoma in adolescents and young adults. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27292.	0.8	24
32	Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 137-145.	0.4	24
33	Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. <i>Annals of Oncology</i> , 2018, 29, 1861-1868.	0.6	135
34	Diagnosis and Management of Acral Lentiginous Melanoma. <i>Current Treatment Options in Oncology</i> , 2018, 19, 42.	1.3	44
36	An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. , 2018, 6, 44.		59
37	Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 639-650.	12.5	152
38	Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 503-520.	1.7	9
39	Metastatic Melanoma: Recent Therapeutic Progress and Future Perspectives. <i>Drugs</i> , 2018, 78, 1197-1209.	4.9	34
40	New Development of Biomarkers for Gastrointestinal Cancers: From Neoplastic Cells to Tumor Microenvironment. <i>Biomedicines</i> , 2018, 6, 87.	1.4	8

#	ARTICLE	IF	CITATIONS
41	Adjuvant Pembrolizumab in Resected Stage III Melanoma. <i>New England Journal of Medicine</i> , 2018, 379, 593-595.	13.9	33
42	Evolving Paradigms in HIV Malignancies: Review of Ongoing Clinical Trials. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1018-1026.	2.3	7
43	Expert opinion on thyroid complications in immunotherapy. <i>Annales D'Endocrinologie</i> , 2018, 79, 555-561.	0.6	33
44	Bigger Is Not Always Better: Tumor Size and Prognosis in Advanced Melanoma. <i>Clinical Cancer Research</i> , 2018, 24, 4915-4917.	3.2	20
45	It is finally time for adjuvant therapy in melanoma. <i>Cancer Treatment Reviews</i> , 2018, 69, 101-111.	3.4	37
46	Immune Checkpoint Blockade across the Cancer Care Continuum. <i>Immunity</i> , 2018, 48, 1077-1080.	6.6	33
47	Rash and Pruritus With PD-1 Inhibitors in Cancer Patients: A Meta-Analysis of Randomized Controlled Trials. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 45-54.	1.0	3
48	Evolving Role of the Oncology Nurse in the Care of Patients with Melanoma. , 2019, , 791-817.		0
49	Cutaneous Adverse Events of Systemic Melanoma Treatments. , 2019, , 743-771.		0
50	Immune checkpoint inhibitors-induced neuromuscular toxicity: From pathogenesis to treatment. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, S74-S85.	1.4	42
51	Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. <i>European Journal of Cancer</i> , 2019, 119, 1-10.	1.3	132
52	Characteristics Associated with Pathologic Nodal Burden in Patients Presenting with Clinical Melanoma Nodal Metastasis. <i>Annals of Surgical Oncology</i> , 2019, 26, 3962-3971.	0.7	5
53	Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanoma. <i>European Journal of Cancer</i> , 2019, 119, 18-29.	1.3	44
54	Neuroblastoma rat sarcoma mutated melanoma: That's what we got so far. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 744-752.	1.5	4
55	New paradigm for stage III melanoma: from surgery to adjuvant treatment. <i>Journal of Translational Medicine</i> , 2019, 17, 266.	1.8	27
56	Differential microglia and macrophage profiles in human IDH-mutant and -wild type glioblastoma. <i>Oncotarget</i> , 2019, 10, 3129-3143.	0.8	71
57	Diagnosing melanoma: the method matters. <i>Medical Journal of Australia</i> , 2019, 211, 209-210.	0.8	1
58	Neoadjuvant Chemotherapy Increases PD-L1 Expression and CD8 ⁺ Tumor-infiltrating Lymphocytes in Esophageal Squamous Cell Carcinoma. <i>Anticancer Research</i> , 2019, 39, 4539-4548.	0.5	44

#	ARTICLE	IF	CITATIONS
59	Neoadjuvant therapy of locally/regionally advanced melanoma. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591986695.	1.4	21
60	Risk-based stratification in head and neck mucosal melanoma. <i>Oral Oncology</i> , 2019, 97, 44-49.	0.8	13
61	Novel Delivery Systems for Checkpoint Inhibitors. <i>Medicines (Basel, Switzerland)</i> , 2019, 6, 74.	0.7	24
62	Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy. <i>Cancer Cell</i> , 2019, 36, 168-178.e4.	7.7	240
63	MYC Expression and Metabolic Redox Changes in Cancer Cells: A Synergy Able to Induce Chemoresistance. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-9.	1.9	17
64	Use of Circulating Tumor DNA for Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 6909-6915.	3.2	34
65	External validation of a prognostic model to predict survival of patients with sentinel node-negative melanoma. <i>British Journal of Surgery</i> , 2019, 106, 1319-1326.	0.1	5
67	Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma. , 2019, 7, 194.		47
68	Integration of radiotherapy and immunotherapy for treatment of oligometastases. <i>Lancet Oncology</i> , The, 2019, 20, e434-e442.	5.1	98
69	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology</i> , The, 2019, 20, e378-e389.	5.1	155
70	Reprogramming lymphocytes for the treatment of melanoma: From biology to therapy. <i>Advanced Drug Delivery Reviews</i> , 2019, 141, 104-124.	6.6	14
71	Retrospective analysis of safety and efficacy of anti-PD-1 therapy and radiation therapy in advanced melanoma: A bi-institutional study. <i>Radiotherapy and Oncology</i> , 2019, 138, 114-120.	0.3	11
72	Focused Ultrasound Surveillance of Lymph Nodes Following Lymphoscintigraphy Without Sentinel Node Biopsy: A Useful and Safe Strategy in Elderly or Frail Melanoma Patients. <i>Annals of Surgical Oncology</i> , 2019, 26, 2855-2863.	0.7	11
73	Isolated limb perfusion and infusion in the treatment of melanoma and soft tissue sarcoma in the era of modern systemic therapies. <i>Journal of Surgical Oncology</i> , 2019, 120, 540-549.	0.8	10
74	Current Immunotherapy Practices in Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 403-418.	0.6	18
75	The Current Landscape of Immune Checkpoint Inhibition for Solid Malignancies. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 369-386.	0.6	19
76	Survival Outcomes of Patients with Clinical Stage III Melanoma in the Era of Novel Systemic Therapies. <i>Annals of Surgical Oncology</i> , 2019, 26, 4621-4630.	0.7	10
77	The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review. <i>Immunotherapy</i> , 2019, 11, 1409-1422.	1.0	28

#	ARTICLE	IF	CITATIONS
78	Survival Comparison between Melanoma Patients Treated with Patient-Specific Dendritic Cell Vaccines and Other Immunotherapies Based on Extent of Disease at the Time of Treatment. <i>Biomedicines</i> , 2019, 7, 80.	1.4	0
79	Primary Excision Margins, Sentinel Lymph Node Biopsy, and Completion Lymph Node Dissection in Cutaneous Melanoma: A Clinical Practice Guideline. <i>Current Oncology</i> , 2019, 26, 541-550.	0.9	34
80	Comparative Safety of PD-1/PD-L1 Inhibitors for Cancer Patients: Systematic Review and Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 972.	1.3	17
81	Monoclonal Antibodies in Dermatocology: State of the Art and Future Perspectives. <i>Cancers</i> , 2019, 11, 1420.	1.7	9
82	Time may Heal All Wounds, but While It Does, Melanoma Marches on. <i>Annals of Surgical Oncology</i> , 2019, 26, 3800-3802.	0.7	1
83	Checkpoint Inhibitor-Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5499-5506.	1.8	85
84	Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma. <i>Melanoma Management</i> , 2019, 6, MMT20.	0.1	9
85	â¬100B as an extra selection tool for FDG PET/CT scanning in follow-up of AJCC stage III melanoma patients. <i>Journal of Surgical Oncology</i> , 2019, 120, 1031-1037.	0.8	6
86	Surgery for Metastatic Melanoma: an Evolving Concept. <i>Current Oncology Reports</i> , 2019, 21, 98.	1.8	11
87	Melanoma-specific survival in patients with positive sentinel lymph nodes: Relevance of sentinel tumor burden. <i>European Journal of Cancer</i> , 2019, 123, 83-91.	1.3	15
88	Oncologic outcomes, prognostic factor analysis and therapeutic algorithm evaluation of head and neck mucosal melanomas in France. <i>European Journal of Cancer</i> , 2019, 123, 1-10.	1.3	25
89	The Role and Necessity of Sentinel Lymph Node Biopsy for Invasive Melanoma. <i>Frontiers in Medicine</i> , 2019, 6, 231.	1.2	11
90	Immune checkpoint inhibitor-associated pituitary-adrenal dysfunction: A systematic review and meta-analysis. <i>Cancer Medicine</i> , 2019, 8, 7503-7515.	1.3	35
92	Managing in-transit melanoma metastases in the new era of effective systemic therapies for melanoma. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 1107-1119.	1.3	11
94	Incidence of Immune Checkpoint Inhibitor-Associated Diabetes: A Meta-Analysis of Randomized Controlled Studies. <i>Frontiers in Pharmacology</i> , 2019, 10, 1453.	1.6	24
95	Efficacy of immune checkpoint inhibitors in cancer patients of different ages: a meta-analysis. <i>Future Oncology</i> , 2019, 15, 3633-3646.	1.1	8
96	Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma. <i>The Cochrane Library</i> , 2019, 7, CD012806.	1.5	22
97	Use of circulating tumoral DNA to guide treatment for metastatic melanoma. <i>Pharmacogenomics</i> , 2019, 20, 1259-1270.	0.6	6

#	ARTICLE	IF	CITATIONS
98	Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors. <i>Antibodies</i> , 2019, 8, 51.	1.2	32
99	Carbon-11 radiotherapy combined with chemotherapy for head and neck mucosal melanoma: Prospective observational study. <i>Cancer Medicine</i> , 2019, 8, 7227-7235.	1.3	19
100	The Prognosis and Natural History of In-Transit Melanoma Metastases at a High-Volume Centre. <i>Annals of Surgical Oncology</i> , 2019, 26, 4673-4680.	0.7	6
101	Indirect Treatment Comparison of Nivolumab Versus Observation or Ipilimumab as Adjuvant Therapy in Resected Melanoma Using Pooled Clinical Trial Data. <i>Advances in Therapy</i> , 2019, 36, 2783-2796.	1.3	9
103	Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?. <i>Annals of Intensive Care</i> , 2019, 9, 25.	2.2	46
104	Practice Patterns and Prognostic Value of Sentinel Lymph Node Biopsy for Thick Melanoma: A National Cancer Database Study. <i>Annals of Surgical Oncology</i> , 2019, 26, 4651-4662.	0.7	9
105	Oncodermatology of the Head and Neck. <i>Facial Plastic Surgery</i> , 2019, 35, 368-376.	0.5	2
106	An indirect treatment comparison of the efficacy of pembrolizumab versus competing regimens for the adjuvant treatment of stage III melanoma. <i>Journal of Drug Assessment</i> , 2019, 8, 135-145.	1.1	8
107	Immunotherapy and urothelial carcinoma: An overview and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 143, 46-55.	2.0	20
108	TNFSF4 (OX40L) expression and survival in locally advanced and metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1493-1500.	2.0	18
109	Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541987635.	0.8	38
110	The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481986976.	1.4	31
111	Cardiotoxicity from immune checkpoint inhibitors. <i>IJC Heart and Vasculature</i> , 2019, 25, 100420.	0.6	79
112	Prospects for combining immune checkpoint blockade with PARP inhibition. <i>Journal of Hematology and Oncology</i> , 2019, 12, 98.	6.9	92
113	A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice. <i>Oncolimmunology</i> , 2019, 8, e1657375.	2.1	56
114	Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2019, 30, 1884-1901.	0.6	394
115	Current concepts of non-coding RNA regulation of immune checkpoints in cancer. <i>Molecular Aspects of Medicine</i> , 2019, 70, 117-126.	2.7	41
116	Upregulation of intratumoral HLA class I and peritumoral Mx1 in ulcerated melanomas. <i>Oncolimmunology</i> , 2019, 8, e1660121.	2.1	4

#	ARTICLE	IF	CITATIONS
117	Cytokine Therapy. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 261-274.	0.9	24
118	Targeted Therapy and Immunotherapy for Melanoma in Japan. <i>Current Treatment Options in Oncology</i> , 2019, 20, 7.	1.3	79
119	Recurrent vulvar melanoma in a patient with neurofibromatosis and gastrointestinal stromal tumour. <i>BMJ Case Reports</i> , 2019, 12, e224744.	0.2	0
120	A nomogram to identify high-risk melanoma patients with a negative sentinel lymph node biopsy. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 722-726.	0.6	14
121	Adjuvant and neoadjuvant cancer therapies: A historical review and a rational approach to understand outcomes. <i>Seminars in Oncology</i> , 2019, 46, 83-99.	0.8	23
122	Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 291-299.	0.9	23
123	<p>Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 4297-4312.	0.9	47
124	Stem Cells Heterogeneity in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2019, , .	0.8	2
125	Photothermal therapy mediated by phase-transformation nanoparticles facilitates delivery of anti-PD1 antibody and synergizes with antitumor immunotherapy for melanoma. <i>Journal of Controlled Release</i> , 2019, 306, 15-28.	4.8	84
126	Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective. <i>Journal of Medical Economics</i> , 2019, 22, 1243-1252.	1.0	10
127	Immune evasion before tumour invasion in early lung squamous carcinogenesis. <i>Nature</i> , 2019, 571, 570-575.	13.7	227
128	Adjuvant Therapy for Melanoma. <i>Current Treatment Options in Oncology</i> , 2019, 20, 63.	1.3	38
129	Adjuvant Treatment of Melanoma: Recent Developments and Future Perspectives. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 817-827.	3.3	29
130	Heterogeneity of Melanoma with Stem Cell Properties. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1139, 105-114.	0.8	3
131	Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2019, 20, 948-960.	5.1	346
132	Real-world data on PD-1 inhibitor therapy in metastatic melanoma. <i>Acta OncolÃ³gica</i> , 2019, 58, 962-966.	0.8	26
133	Cancer treatment and survivorship statistics, 2019. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 363-385.	157.7	3,303
134	Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2019, 116, 148-157.	1.3	64

#	ARTICLE	IF	CITATIONS
135	Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events. <i>Frontiers in Medicine</i> , 2019, 6, 119.	1.2	145
136	Vulvar melanoma: management of primary disease and repeated recurrences. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1077-1081.	1.2	3
137	A Population-Based Comparison of the AJCC 7th and AJCC 8th Editions for Patients Diagnosed with Stage III Cutaneous Malignant Melanoma in Sweden. <i>Annals of Surgical Oncology</i> , 2019, 26, 2839-2845.	0.7	16
138	Approaches to High-Risk Resected Stage II and III Melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e207-e211.	1.8	18
139	An updated analysis of 4 randomized ECOG trials of high-dose interferon in the adjuvant treatment of melanoma. <i>Cancer</i> , 2019, 125, 3013-3024.	2.0	14
140	Clinico-pathological associations and concomitant mutations of the RAS/RAF pathway in metastatic colorectal cancer. <i>Journal of Translational Medicine</i> , 2019, 17, 137.	1.8	13
141	Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 563-580.	12.5	1,235
143	How can clinical research improve European health outcomes in cancer?. <i>Journal of Cancer Policy</i> , 2019, 20, 100182.	0.6	10
144	Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States. <i>Journal of Medical Economics</i> , 2019, 22, 981-993.	1.0	20
145	Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials. <i>JAMA Oncology</i> , 2019, 5, 1008.	3.4	526
146	Immune checkpoint inhibition for the treatment of mesothelioma. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 697-706.	1.4	18
147	Classification of 3097 patients from the Japanese melanoma study database using the American joint committee on cancer eighth edition cancer staging system. <i>Journal of Dermatological Science</i> , 2019, 94, 284-289.	1.0	13
148	The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment. <i>Clinical Cancer Research</i> , 2019, 25, 5743-5751.	3.2	129
149	Current and emerging systemic therapies for cutaneous metastatic melanoma. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1135-1152.	0.9	33
150	Novel Approaches to Improve the Efficacy of Immuno-Radiotherapy. <i>Frontiers in Oncology</i> , 2019, 9, 156.	1.3	119
151	Cutaneous Adverse Events of Systemic Melanoma Treatments. , 2019, , 1-29.		0
152	Early Recurrence in Completely Resected IIIB and IIIC Melanoma Warrants Restaging Prior to Adjuvant Therapy. <i>Annals of Surgical Oncology</i> , 2019, 26, 3945-3952.	0.7	24
153	Similar survival outcome after endoscopic and open approaches for sinonasal mucosal melanoma. <i>Rhinology</i> , 2019, 57, 0-0.	0.7	9

#	ARTICLE	IF	CITATIONS
154	Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy. <i>Trends in Immunology</i> , 2019, 40, 328-344.	2.9	160
155	Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA. <i>Annals of Oncology</i> , 2019, 30, 804-814.	0.6	117
156	An update on head and neck cancer: new entities and their histopathology, molecular background, treatment, and outcome. <i>Apmis</i> , 2019, 127, 240-264.	0.9	26
157	Kein Äberlebensvorteil beim SentinelÄlymphknotenÄpositiven Melanom mit sofortiger kompletter Lymphadenektomie ÄÄ eine Äbersicht. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 7-14.	0.4	0
158	Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome. <i>Oncolimmunology</i> , 2019, 8, e1581530.	2.1	69
159	Meta-analysis of completion lymph node dissection in sentinel lymph node-positive melanoma. <i>British Journal of Surgery</i> , 2019, 106, 672-681.	0.1	15
160	False-Positive Results and Incidental Findings with Annual CT or PET/CT Surveillance in Asymptomatic Patients with Resected Stage III Melanoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 1860-1868.	0.7	29
161	An immunophenotyping of renal clear cell carcinoma with characteristics and a potential therapeutic target for patients insensitive to immune checkpoint blockade. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 13330-13341.	1.2	16
162	Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 701-710.	5.1	50
163	Immunotherapy of Melanoma: Facts and Hopes. <i>Clinical Cancer Research</i> , 2019, 25, 5191-5201.	3.2	181
164	Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients. <i>Annals of Oncology</i> , 2019, 30, 815-822.	0.6	77
165	Clinical Pharmacokinetic and Pharmacodynamic Considerations in the (Modern) Treatment of Melanoma. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1029-1043.	1.6	6
166	What Is the Role of Dabrafenib Plus Trametinib Adjuvant Therapy in Stage IIIA Melanoma?. <i>Journal of Clinical Oncology</i> , 2019, 37, 1355-1356.	0.8	7
167	Ex vivo Hsp70-Activated NK Cells in Combination With PD-1 Inhibition Significantly Increase Overall Survival in Preclinical Models of Glioblastoma and Lung Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 454.	2.2	48
168	Immunotherapy Bridge 2018 and Melanoma Bridge 2018: meeting abstracts. <i>Journal of Translational Medicine</i> , 2019, 17, 1-18.	1.8	1
169	Adjuvant Treatment of Hepatocellular Carcinoma: Prospect of Immunotherapy. <i>Hepatology</i> , 2019, 70, 1437-1442.	3.6	104
170	Estimation of Distant MetastasisÄÄfree Survival in Trials of Adjuvant Therapy for Melanoma. <i>New England Journal of Medicine</i> , 2019, 380, 1374-1377.	13.9	4
171	Genomic stratification and liquid biopsy in a rare adrenocortical carcinoma (ACC) case, with dual lung metastases. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a003764.	0.5	7

#	ARTICLE	IF	CITATIONS
172	Unlocking the therapeutic potential of primary tumor-draining lymph nodes. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1681-1688.	2.0	56
173	Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma. <i>Cancer Medicine</i> , 2019, 8, 2205-2212.	1.3	58
174	Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors. , 2019, 7, 53.		59
175	Completion Node Dissection for Sentinel Node-Positive Melanoma: Can a Systematic Review Bring One Discussion to a Close While Leaving the Broader Conversation Still Open?. <i>Annals of Surgical Oncology</i> , 2019, 26, 921-923.	0.7	0
176	Poly-specific neoantigen-targeted cancer vaccines delay patient derived tumor growth. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 78.	3.5	32
177	Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy. <i>Clinical and Translational Oncology</i> , 2019, 21, 774-780.	1.2	7
178	Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. <i>Nature Medicine</i> , 2019, 25, 470-476.	15.2	459
179	Prospective cohort study of ultrasound surveillance of regional lymph nodes in patients with intermediate-risk cutaneous melanoma. <i>British Journal of Surgery</i> , 2019, 106, 729-734.	0.1	6
180	The extent of surgery for stage III melanoma: how much is appropriate?. <i>Lancet Oncology</i> , The, 2019, 20, e167-e174.	5.1	27
181	Do Not Forget About the Importance of Loco-Regional Therapy in Melanoma Management. <i>Seminars in Radiation Oncology</i> , 2019, 29, 166-170.	1.0	3
182	Many ways to resistance: How melanoma cells evade targeted therapies. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 313-322.	3.3	166
183	Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors. <i>Oncolmmunology</i> , 2019, 8, e1568812.	2.1	148
184	Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients's treatment. <i>Journal of Thoracic Disease</i> , 2019, 11, 35-38.	0.6	28
185	Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 391-407.	3.3	35
186	The pioneers behind immune checkpoint blockers awarded the Nobel Prize in physiology or medicine 2018. <i>Acta OncolÃ³gica</i> , 2019, 58, 1-8.	0.8	14
187	Base excision repair regulates PD-L1 expression in cancer cells. <i>Oncogene</i> , 2019, 38, 4452-4466.	2.6	70
188	Immunotherapy for skin cancer. <i>International Immunology</i> , 2019, 31, 465-475.	1.8	47
189	How I treat metastatic melanoma. <i>ESMO Open</i> , 2019, 4, e000509.	2.0	2

#	ARTICLE	IF	CITATIONS
190	Current standards of care for melanoma excision in Australasia. <i>Journal of Primary Health Care</i> , 2019, 11, 193.	0.2	0
191	Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma. <i>Translational Cancer Research</i> , 2019, 8, S585-S588.	0.4	1
192	Repurposing Drugs for Cancer Radiotherapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2019, 25, 106-115.	1.0	8
193	Preferences of Canadian Patients and Physicians for Adjuvant Treatments for Melanoma. <i>Current Oncology</i> , 2019, 26, 755-765.	0.9	7
195	Primary Malignant Melanoma of the Bladder Treated by Robotic Partial Cystectomy and Immunotherapy. <i>Journal of Endourology Case Reports</i> , 2019, 5, 151-153.	0.3	4
196	Type 1 diabetes mellitus in a melanoma patient treated with adjuvant nivolumab therapy. <i>Journal of Cutaneous Immunology and Allergy</i> , 2019, 2, 176-177.	0.2	1
197	Management of V600E and V600K BRAF-Mutant Melanoma. <i>Current Treatment Options in Oncology</i> , 2019, 20, 81.	1.3	28
198	Immunization With the CSF-470 Vaccine Plus BCG and rhGM-CSF Induced in a Cutaneous Melanoma Patient a TCR ¹ Repertoire Found at Vaccination Site and Tumor Infiltrating Lymphocytes That Persisted in Blood. <i>Frontiers in Immunology</i> , 2019, 10, 2213.	2.2	9
199	Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review. <i>Melanoma Management</i> , 2019, 6, MMT33.	0.1	6
200	HVEM has a broader expression than PD-L1 and constitutes a negative prognostic marker and potential treatment target for melanoma. <i>Oncimmunology</i> , 2019, 8, e1665976.	2.1	35
201	An open source automated tumor infiltrating lymphocyte algorithm for prognosis in melanoma. <i>Nature Communications</i> , 2019, 10, 5440.	5.8	62
202	Immunobiology of Uveal Melanoma: State of the Art and Therapeutic Targets. <i>Frontiers in Oncology</i> , 2019, 9, 1145.	1.3	36
203	Indirect comparison between immune checkpoint inhibitors and targeted therapies for the treatment of melanoma. <i>Journal of Cancer</i> , 2019, 10, 6114-6123.	1.2	3
204	The Evolution of Adjuvant Therapy for Melanoma. <i>Current Oncology Reports</i> , 2019, 21, 106.	1.8	23
205	Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. , 2019, 7, 319.		164
206	Adjuvant systemic therapy in high-risk melanoma. <i>Melanoma Research</i> , 2019, 29, 358-364.	0.6	16
207	An update on adjuvant systemic therapies in melanoma. <i>Melanoma Management</i> , 2019, 6, MMT28.	0.1	10
208	Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer. <i>European Respiratory Review</i> , 2019, 28, 190058.	3.0	73

#	ARTICLE	IF	CITATIONS
210	Checkpoints inhibitors in the (neo)adjuvant setting of solid tumors. <i>Current Opinion in Oncology</i> , 2019, 31, 439-444.	1.1	3
211	Vulvar malignancies: an interdisciplinary perspective. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 1257-1276.	0.4	28
212	Immune checkpoint inhibitor myocarditis. <i>Current Opinion in Cardiology</i> , 2019, 34, 303-306.	0.8	13
213	<p>Sentinel Lymph Node Biopsy Was Associated With Favorable Survival Outcomes For Patients With Clinically Node-Negative Asian Melanoma</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 9655-9664.	0.9	6
214	Comparative efficacy and safety of dabrafenib in combination with trametinib versus competing adjuvant therapies for high-risk melanoma. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 1349-1363.	0.6	5
215	Correlation of Tumor Burden in Sentinel Lymph Nodes with Tumor Burden in Nonsentinel Lymph Nodes and Survival in Cutaneous Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 7585-7593.	3.2	17
216	Setting the scene â€“ a future â€“epidemicâ€™ of immune-related adverse events in association with checkpoint inhibitor therapy. <i>Rheumatology</i> , 2019, 58, vii1-vii6.	0.9	3
219	Rational combination of cancer immunotherapy in melanoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 433-447.	1.4	7
220	Tackling melanoma by adjuvant therapy: why, whom and how?. <i>British Journal of Dermatology</i> , 2019, 180, 1-2.	1.4	3
221	Recent developments in lymph node surgery for melanoma. <i>British Journal of Dermatology</i> , 2019, 180, 5-7.	1.4	5
222	Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 197-218.	21.5	2,005
223	Cutaneous Melanomaâ€™A Review in Detection, Staging, and Management. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 25-38.	0.9	85
224	Updates in adjuvant systemic therapy for melanoma. <i>Journal of Surgical Oncology</i> , 2019, 119, 222-231.	0.8	35
225	Management of inâ€“transit melanoma metastases: a review. <i>ANZ Journal of Surgery</i> , 2019, 89, 647-652.	0.3	18
226	Batf3⁺ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy. <i>Oncolimmunology</i> , 2019, 8, e1546068.	2.1	42
227	Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2019, 106, 12-23.	1.3	171
228	Adjuvant and Neoadjuvant Treatment of Skin Cancer. <i>Facial Plastic Surgery Clinics of North America</i> , 2019, 27, 139-150.	0.9	8
229	Validation of a Nomogram for Non-sentinel Node Positivity in Melanoma Patients, and Its Clinical Implications: A Brazilianâ€™Dutch Study. <i>Annals of Surgical Oncology</i> , 2019, 26, 395-405.	0.7	16

#	ARTICLE	IF	CITATIONS
230	Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 1272-1279.	3.2	57
231	Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 2442-2449.	3.2	106
232	Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 429-443.	1.2	13
233	Revolutionizing treatment of advanced melanoma with immunotherapy. <i>Surgical Oncology</i> , 2019, , 101180.	0.8	12
234	Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage IIâ€“III Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 2494-2502.	3.2	18
235	Prognostic Impact of Tumor-Infiltrating Lymphocytes and Neutrophils on Survival of Patients with Upfront Resection of Pancreatic Cancer. <i>Cancers</i> , 2019, 11, 39.	1.7	84
236	Clinical characterization of colitis arising from anti-PD-1 based therapy. <i>Oncolimmunology</i> , 2019, 8, e1524695.	2.1	44
237	Lack of survival benefit in sentinel lymph nodeâ€‘positive melanoma with immediate complete lymphadenectomy â€‘ a review. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 7-13.	0.4	11
238	Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 511-521.	1.2	153
239	Identification of risk in cutaneous melanoma patients: Prognostic and predictive markers. <i>Journal of Surgical Oncology</i> , 2019, 119, 175-186.	0.8	32
240	Management of local or regional nonâ€‘nodal disease. <i>Journal of Surgical Oncology</i> , 2019, 119, 187-199.	0.8	8
242	Cancer immunoediting and resistance to T cell-based immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 151-167.	12.5	1,093
243	Uncertain diagnosis and prognosis in advanced melanoma: a qualitative study of the experiences of bereaved carers in a time of immune and targeted therapies. <i>British Journal of Dermatology</i> , 2019, 180, 1368-1376.	1.4	10
244	Development and validation of a nomogram to predict recurrence and melanoma-specific mortality in patients with negative sentinel lymph nodes. <i>British Journal of Surgery</i> , 2019, 106, 217-225.	0.1	34
245	Immune checkpoint inhibitor rechallenge in patients with immune-related myositis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e129-e129.	0.5	30
246	The Role of Completion Lymph Node Dissection for Sentinel Lymph Node-Positive Melanoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 1028-1034.	0.7	13
247	Treatment of melanoma of unknown primary in the era of immunotherapy and targeted therapy: A Dutch populationâ€‘based study. <i>International Journal of Cancer</i> , 2020, 146, 26-34.	2.3	28
248	The Sunbelt Melanoma Trial. <i>Annals of Surgical Oncology</i> , 2020, 27, 28-34.	0.7	20

#	ARTICLE	IF	CITATIONS
249	Modelling Survival of Patients Treated with Adjuvant Nivolumab Who Have Melanoma with Lymph Node Involvement or Metastatic Disease After Complete Resection. <i>Pharmacoeconomics - Open</i> , 2020, 4, 343-351.	0.9	4
250	Response of patients with melanoma to immune checkpoint blockade“ insights gleaned from analysis of a new mathematical mechanistic model. <i>Journal of Theoretical Biology</i> , 2020, 485, 110033.	0.8	17
251	Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 723-733.	5.7	102
253	Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti“PD therapy. <i>Cancer</i> , 2020, 126, 86-97.	2.0	113
254	Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 1-11.	3.3	13
255	Sentinel Node Biopsy for Melanoma Patients with a Local Recurrence or In-Transit Metastasis. <i>Annals of Surgical Oncology</i> , 2020, 27, 561-568.	0.7	6
256	Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition. <i>International Journal of Clinical Oncology</i> , 2020, 25, 217-239.	1.0	17
257	Current role of sentinel lymph node biopsy in the management of cutaneous melanoma: A UK consensus statement. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2020, 73, 36-42.	0.5	36
258	Cranial nerve outcomes in regionally recurrent head & neck melanoma after sentinel lymph node biopsy. <i>Laryngoscope</i> , 2020, 130, 1707-1714.	1.1	4
259	Current Immunotherapeutic Strategies in Cancer. <i>Recent Results in Cancer Research</i> , 2020, , .	1.8	4
260	Principles of Immunotherapy in Melanoma. <i>Surgical Clinics of North America</i> , 2020, 100, 161-173.	0.5	28
262	Surgical Considerations and Systemic Therapy of Melanoma. <i>Surgical Clinics of North America</i> , 2020, 100, 141-159.	0.5	4
263	Principles of Targeted Therapy for Melanoma. <i>Surgical Clinics of North America</i> , 2020, 100, 175-188.	0.5	40
264	Fertility Challenges and Solutions in Women with Cancer. , 2020, , .		0
265	Preferences for Immunotherapy in Melanoma: A Systematic Review. <i>Annals of Surgical Oncology</i> , 2020, 27, 571-584.	0.7	36
266	Current management of patients with melanoma who are found to be sentinel node-positive. <i>ANZ Journal of Surgery</i> , 2020, 90, 491-496.	0.3	12
267	ASO Author Reflections: Important Factors for Adjuvant Immunotherapy Treatment Decisions for Stage II-IV Melanoma Patients and Their Clinicians. <i>Annals of Surgical Oncology</i> , 2020, 27, 585-586.	0.7	0
268	Risk of immune-related diarrhea with PD-1/PD-L1 inhibitors in different cancer types and treatment regimens. <i>Journal of Cancer</i> , 2020, 11, 41-50.	1.2	3

#	ARTICLE	IF	CITATIONS
269	Adjuvant therapy for cutaneous melanoma: a systematic review and network meta-analysis of new therapies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 956-966.	1.3	19
270	Bioactive lipids as modulators of immune check point inhibitors. <i>Medical Hypotheses</i> , 2020, 135, 109473.	0.8	10
271	When food regimes become hegemonic: Agrarian India through a Gramscian lens. <i>Journal of Agrarian Change</i> , 2020, 20, 188-206.	0.8	8
272	Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 358-365.	1.5	51
273	Homogeneous, Low-volume, Efficient, and Sensitive Quantitation of Circulating Exosomal PD-L1 for Cancer Diagnosis and Immunotherapy Response Prediction. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 4800-4805.	7.2	159
274	The impact of the immunotherapy revolution on lymph nodal surgery. <i>Bulletin Du Cancer</i> , 2020, 107, 640-641.	0.6	1
275	Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutation-positive melanoma receiving adjuvant vemurafenib. <i>Annals of Oncology</i> , 2020, 31, 153-159.	0.6	25
276	The challenge of identifying which stage III melanoma patients need adjuvant treatment and with what. <i>Annals of Oncology</i> , 2020, 31, 11-12.	0.6	2
277	Novedades terapéuticas en dermatología. <i>Piel</i> , 2020, 35, 4-9.	0.0	0
278	Neoadjuvant Versus Adjuvant Immune Checkpoint Blockade in the Treatment of Clinical Stage III Melanoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 2915-2926.	0.7	11
279	Considering adjuvant therapy for stage II melanoma. <i>Cancer</i> , 2020, 126, 1166-1174.	2.0	32
280	European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment Update 2019. <i>European Journal of Cancer</i> , 2020, 126, 159-177.	1.3	154
281	Tumor intrinsic and extrinsic immune functions of CD155. <i>Seminars in Cancer Biology</i> , 2020, 65, 189-196.	4.3	85
282	Precision Medicine in the Treatment of Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 1-13.	0.6	7
283	Thick melanomas without lymph node metastases: A forgotten group with poor prognosis. <i>European Journal of Surgical Oncology</i> , 2020, 46, 918-923.	0.5	4
284	Cancer immunotherapy with immunoadjuvants, nanoparticles, and checkpoint inhibitors: Recent progress and challenges in treatment and tracking response to immunotherapy. , 2020, 207, 107456.		42
285	Surgical approach to patients with low-burden stage III melanoma: Is it time to consider conservative surgery?. <i>European Journal of Surgical Oncology</i> , 2020, 46, 498-500.	0.5	3
286	Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo. <i>JAMA Oncology</i> , 2020, 6, 519.	3.4	287

#	ARTICLE	IF	CITATIONS
289	Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma. <i>European Journal of Cancer</i> , 2020, 125, 38-45.	1.3	36
290	First Eastern European experience of isolated limb infusion for in-transit metastatic melanoma confined to the limb: Is it still an effective treatment option in the modern era?. <i>European Journal of Surgical Oncology</i> , 2020, 46, 272-276.	0.5	1
291	External validation of the American Joint Committee on Cancer 8th edition melanoma staging system: who needs adjuvant treatment?. <i>Melanoma Research</i> , 2020, 30, 185-192.	0.6	17
292	Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma. <i>Cancer Immunology Research</i> , 2020, 8, 70-80.	1.6	47
293	Malignant Melanoma of the Vulva and Vagina: A US Population-Based Study of 1863 Patients. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 285-295.	3.3	60
294	Review article: new therapeutic interventions for advanced hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 78-89.	1.9	71
295	Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. <i>Oncologist</i> , 2020, 25, e398-e404.	1.9	10
296	Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease. <i>British Journal of Dermatology</i> , 2020, 183, 559-563.	1.4	18
297	Japanese Dermatological Association Guidelines: Outlines of guidelines for cutaneous melanoma 2019. <i>Journal of Dermatology</i> , 2020, 47, 89-103.	0.6	33
298	Melanoma pathology reporting and staging. <i>Modern Pathology</i> , 2020, 33, 15-24.	2.9	61
299	Impact of PD-L1 expression and human papillomavirus status in anti-PD1/PDL1 immunotherapy for head and neck squamous cell carcinoma: Systematic review and meta-analysis. <i>Head and Neck</i> , 2020, 42, 774-786.	0.9	52
301	Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609. <i>Journal of Clinical Oncology</i> , 2020, 38, 567-575.	0.8	122
302	Regional Node Basin Recurrence in Melanoma Patients: More Common After Node Dissection for Macroscopic Rather than Clinically Occult Nodal Disease. <i>Annals of Surgical Oncology</i> , 2020, 27, 1970-1977.	0.7	3
303	Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting. <i>Current Opinion in Oncology</i> , 2020, 32, 106-113.	1.1	52
304	KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. <i>Future Oncology</i> , 2020, 16, 4429-4438.	1.1	59
305	Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque. <i>Circulation</i> , 2020, 142, 2299-2311.	1.6	282
306	An atypical sarcoid-like reaction during anti-protein death 1 treatment in a patient with metastatic melanoma. <i>Melanoma Research</i> , 2020, 30, 524-527.	0.6	5
307	Subversion of Ras Small GTPases in Cutaneous Melanoma Aggressiveness. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 575223.	1.8	5

#	ARTICLE	IF	CITATIONS
308	Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade. <i>IScience</i> , 2020, 23, 101580.	1.9	22
309	Is the neutrophil-to-lymphocyte ratio a useful prognostic indicator in melanoma patients?. <i>Melanoma Management</i> , 2020, 7, MMT47.	0.1	24
310	Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model. <i>European Journal of Cancer</i> , 2020, 140, 11-18.	1.3	31
311	The relationship between pneumonitis and programmed cell death-1/programmed cell death ligand 1 inhibitors among cancer patients. <i>Medicine (United States)</i> , 2020, 99, e22567.	0.4	5
312	Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy. , 2020, 8, e000867.		81
313	Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma. <i>Annals of Oncology</i> , 2020, 31, 1569-1579.	0.6	18
314	Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188447.	3.3	97
315	Increased risk of immune checkpoint inhibitor-induced type 1 diabetes mellitus with the new approved 6-week scheme of pembrolizumab in patients with melanoma?. <i>European Journal of Cancer</i> , 2020, 138, 169-171.	1.3	3
316	Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy. <i>Cancers</i> , 2020, 12, 2870.	1.7	64
317	Cost-Effective Patient Selection for Adjuvant Therapy in Stage IIIA Melanoma. <i>Journal of the American College of Surgeons</i> , 2020, 231, 554-556.	0.2	1
319	Recent advances of molecular mechanisms of regulating PD-L1 expression in melanoma. <i>International Immunopharmacology</i> , 2020, 88, 106971.	1.7	7
320	Relevance of sentinel lymph node biopsy for thick melanoma in the era of immunotherapy. <i>Surgical Oncology</i> , 2020, 35, 309-314.	0.8	0
321	Rational use of 18F-FDG PET/CT in patients with advanced cutaneous melanoma: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103044.	2.0	29
322	Factors predicting toxicity and response following isolated limb infusion for melanoma: An international multi-centre study. <i>European Journal of Surgical Oncology</i> , 2020, 46, 2140-2146.	0.5	8
323	Targeted and immunotherapies in <i>BRAF</i> mutant melanoma: where we stand and what to expect. <i>British Journal of Dermatology</i> , 2021, 185, 253-262.	1.4	20
324	Current Perspectives on Immunotherapy in the Peri-Operative Setting of Muscle-Infiltrating Bladder Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 568279.	1.3	11
325	Cost-Benefit Implication of Gene Expression Profiling and Adjuvant Therapy in Stage IIIA Melanoma. <i>Journal of the American College of Surgeons</i> , 2020, 231, 547-554e1.	0.2	8
326	Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects. <i>Cancers</i> , 2020, 12, 3456.	1.7	12

#	ARTICLE	IF	CITATIONS
327	Cutaneous melanoma and the immunotherapy revolution (Review). International Journal of Oncology, 2020, 57, 609-618.	1.4	75
328	Pembrolizumab in Microsatellite-Instabilityâ€“High Advanced Colorectal Cancer. New England Journal of Medicine, 2020, 383, 2207-2218.	13.9	1,513
329	Radiotherapy for malignant melanoma of the lacrimal sac. Rare Tumors, 2020, 12, 203636132097194.	0.3	3
331	Evolving impact of long-term survival results on metastatic melanoma treatment. , 2020, 8, e000948.		59
332	Sentinel Node Status is the Most Important Prognostic Information for Clinical Stage IIB and IIC Melanoma Patients. Annals of Surgical Oncology, 2020, 27, 4133-4140.	0.7	9
333	Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens. International Immunopharmacology, 2020, 87, 106770.	1.7	7
334	Adjuvant Therapy for Melanoma: Past, Current, and Future Developments. Cancers, 2020, 12, 1994.	1.7	26
335	PD-L1 Expression Affects Neoantigen Presentation. IScience, 2020, 23, 101238.	1.9	9
336	Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives. British Journal of Cancer, 2020, 123, 885-897.	2.9	22
337	Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research. Lancet Oncology, The, 2020, 21, e398-e404.	5.1	74
338	Molecular biology in conjunctival melanoma and the relationship to mucosal melanoma. Acta Ophthalmologica, 2020, 98, 1-27.	0.6	13
339	<p>Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context</p>. OncoTargets and Therapy, 2020, Volume 13, 6885-6896.	1.0	1
340	A decade of immune-checkpoint inhibitors in cancer therapy. Nature Communications, 2020, 11, 3801.	5.8	920
341	Complete response with talimogene laherparepvec in recurrent melanoma of the ear: A case report. Oral Oncology, 2020, 111, 104899.	0.8	0
342	Toxicity in combination immune checkpoint inhibitor and radiation therapy: A systematic review and meta-analysis. Radiotherapy and Oncology, 2020, 151, 141-148.	0.3	62
343	â€œTo Anticipateâ€ Neoadjuvant Therapy in Melanoma with a Focus on Predictive Biomarkers. Cancers, 2020, 12, 1941.	1.7	4
344	Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy. Cancers, 2020, 12, 1943.	1.7	18
345	Sentinel Node Biopsy in Patients With Thin Melanoma: A Need to Better Define the Aim. Journal of Clinical Oncology, 2020, 38, 3237-3238.	0.8	1

#	ARTICLE	IF	CITATIONS
346	The use of FDGâ€PET/CT to detect early recurrence after resection of highâ€risk stage III melanoma. <i>Journal of Surgical Oncology</i> , 2020, 122, 1328-1336.	0.8	4
347	Different patterns of treatmentâ€related adverse events of programmed cell deathâ€1 and its ligandâ€1 inhibitors in different cancer types: A metaâ€analysis and systemic review of clinical trials. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, e160-e178.	0.7	6
349	The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies. <i>BMC Cancer</i> , 2020, 20, 1018.	1.1	23
350	A Systematic Review and Meta-Analysis of Immune-Related Adverse Events of Anti-PD-1 Drugs in Randomized Controlled Trials. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382096745.	0.8	9
351	Comparative Analysis of Acral Melanoma in Chinese and Caucasian Patients. <i>Journal of Skin Cancer</i> , 2020, 2020, 1-8.	0.5	5
352	Peritumoral Immune Infiltrate as a Prognostic Biomarker in Thin Melanoma. <i>Frontiers in Immunology</i> , 2020, 11, 561390.	2.2	12
353	ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. <i>Annals of Oncology</i> , 2020, 31, 1449-1461.	0.6	69
354	Incidence and Risk of Colitis With Programmed Death 1 Versus Programmed Death Ligand 1 Inhibitors for the Treatment of Cancer. <i>Journal of Immunotherapy</i> , 2020, 43, 291-298.	1.2	7
355	Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. <i>New England Journal of Medicine</i> , 2020, 383, 1139-1148.	13.9	256
356	Safety of pembrolizumab for resected stage III melanoma. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1221-1227.	1.0	3
357	The current state of adjuvant therapy of melanoma. <i>Lancet Oncology</i> , The, 2020, 21, 1394-1395.	5.1	12
358	Adjuvant nivolumab versus ipilimumab in resected stage IIIâ€C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1465-1477.	5.1	330
359	Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1664-1674.	0.4	41
360	Updates in the evidenceâ€based management of cutaneous melanoma. <i>Head and Neck</i> , 2020, 42, 3396-3404.	0.9	3
361	Perspectives in melanoma: meeting report from the â€Melanoma Bridgeâ€ (December 5thâ€7th, 2019,) Tj ETQq0,0 0 rgBT /Overlock	1.8	5
362	Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3925-3936.	0.8	192
363	Costâ€Utility Analysis of Nivolumab in Adjuvant Treatment of Melanoma in France. <i>Dermatology and Therapy</i> , 2020, 10, 1331-1343.	1.4	7
364	<p>Effect of Chitosan Magnetic Nanoparticles Loaded with Ang2-siRNA Plasmids on the Growth of Melanoma Xenografts in Nude Mice</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 7475-7485.	0.9	12

#	ARTICLE	IF	CITATIONS
365	<p>Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy</p>. Drug Design, Development and Therapy, 2020, Volume 14, 3625-3649.	2.0	80
366	Disparity in outcomes of melanoma adjuvant immunotherapy by demographic profile. Melanoma Management, 2020, 7, MMT43.	0.1	7
367	Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma. Cancers, 2020, 12, 2329.	1.7	45
368	Pan-cancer analysis of genomic properties and clinical outcome associated with tumor tertiary lymphoid structure. Scientific Reports, 2020, 10, 21530.	1.6	49
369	Choosing PD-1 Inhibitors in Oncology Setting, Left or Right?â€”Lessons From Value Assessment With ASCO-VF and ESMO-MCBS. Frontiers in Pharmacology, 2020, 11, 574511.	1.6	5
370	NAMPT Over-Expression Recapitulates the BRAF Inhibitor Resistant Phenotype Plasticity in Melanoma. Cancers, 2020, 12, 3855.	1.7	17
371	The molecular profile of mucosal melanoma. Melanoma Research, 2020, 30, 533-542.	0.6	14
372	Toxicities from immunotherapy: From clinical trials to real-world clinical practice. Medicina Clínica (English Edition), 2020, 155, 541-547.	0.1	0
373	Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab. , 2020, 8, e001488.		22
374	<p>Review of Adjuvant Therapies in Renal Cell Carcinoma: Evidence to Date</p>. OncoTargets and Therapy, 2020, Volume 13, 12301-12316.	1.0	22
375	Comparative Risks of High-Grade Adverse Events Among FDA-Approved Systemic Therapies in Advanced Melanoma: Systematic Review and Network Meta-Analysis. Frontiers in Oncology, 2020, 10, 571135.	1.3	2
376	Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities. Frontiers in Immunology, 2020, 11, 598877.	2.2	133
378	When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report. , 2020, 8, e001322.		26
379	Stadium III Melanom: KÃ¶nnen immunologische Nebenwirkungen ein gutes Zeichen sein?. Karger Kompass Onkologie, 2020, 7, 138-139.	0.0	0
380	Checkpoint Inhibitors in Gynecological Malignancies: Are we There Yet?. BioDrugs, 2020, 34, 749-762.	2.2	5
381	Future of immune checkpoint inhibitors: focus on tumor immune microenvironment. Annals of Translational Medicine, 2020, 8, 1095-1095.	0.7	27
382	Imaging Intensity and Survival Outcomes in High-Risk Resected Melanoma Treated by Systemic Therapy at Recurrence. Annals of Surgical Oncology, 2020, 27, 3683-3691.	0.7	13
383	Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapyâ†. Annals of Oncology, 2020, 31, 1075-1082.	0.6	62

#	ARTICLE	IF	CITATIONS
384	Toripalimab for the treatment of melanoma. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 863-869.	1.4	15
385	An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA. <i>Clinical Drug Investigation</i> , 2020, 40, 629-643.	1.1	13
386	Current Panorama and Challenges for Neoadjuvant Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 5068-5077.	3.2	34
387	Immune-related adverse events of checkpoint inhibitors. <i>Nature Reviews Disease Primers</i> , 2020, 6, 38.	18.1	684
388	Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1736-1752.	1.1	10
389	New pathways in immune stimulation: targeting OX40. <i>ESMO Open</i> , 2020, 5, e000573.	2.0	56
390	Hydroxymethylation and tumors: can 5-hydroxymethylation be used as a marker for tumor diagnosis and treatment?. <i>Human Genomics</i> , 2020, 14, 15.	1.4	29
391	Elderly Age Is Associated With More Conservative Treatment of Invasive Melanoma. <i>Anticancer Research</i> , 2020, 40, 2895-2903.	0.5	4
392	Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 491-501.	1.1	14
393	Efficacy of immune checkpoint inhibitors and age in cancer patients. <i>Immunotherapy</i> , 2020, 12, 587-603.	1.0	21
394	Metastatic melanoma: therapeutic agents in preclinical and early clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 739-753.	1.9	2
395	Treatment of High Risk Resected Melanoma in Australia: Current Landscape and Practises. <i>Australasian Journal of Dermatology</i> , 2020, 61, 203-209.	0.4	4
396	Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2020, 395, 1558-1568.	6.3	188
397	Adjuvant immunotherapy: the sting in the tail. <i>European Journal of Cancer</i> , 2020, 132, 207-210.	1.3	20
398	EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma. <i>Journal of Investigative Dermatology</i> , 2020, 140, 2442-2454.e5.	0.3	46
399	The Landmark Series: Neoadjuvant Systemic Therapy (NAST) for Stage 3 Melanoma Patients â€“ A Potential Paradigm Shift in Management. <i>Annals of Surgical Oncology</i> , 2020, 27, 2188-2200.	0.7	4
400	Molecular Biochemical Aspects of Cancer. , 2020, , .		3
401	Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial. <i>European Journal of Cancer</i> , 2020, 133, 94-103.	1.3	13

#	ARTICLE	IF	CITATIONS
402	The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel nodeâ€“positive melanoma without the need for completion lymph node dissection. <i>European Journal of Cancer</i> , 2020, 134, 9-18.	1.3	11
404	The role of immune checkpoint inhibitor therapy in advanced adrenocortical carcinoma revisited: review of literature. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1531-1542.	1.8	18
405	Systemic adjuvant therapy for adult patients at high risk for recurrent melanoma: A systematic review. <i>Cancer Treatment Reviews</i> , 2020, 87, 102032.	3.4	13
406	Management of Regional Nodal Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 415-431.	0.6	1
407	Neoadjuvant Therapy for Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 445-453.	0.6	2
408	From Tank to Treatment: Modeling Melanoma in Zebrafish. <i>Cells</i> , 2020, 9, 1289.	1.8	17
409	Improved Risk Prediction Calculator for Sentinel Node Positivity in Patients With Melanoma: The Melanoma Institute Australia Nomogram. <i>Journal of Clinical Oncology</i> , 2020, 38, 2719-2727.	0.8	84
410	Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts. <i>Journal of Clinical Oncology</i> , 2020, 38, 2543-2551.	0.8	40
411	Adjuvant Nodal Radiation Therapy for Melanoma in the Era of Immunotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 164-169.	0.4	6
412	Combination checkpoint blockade for metastatic cutaneous malignancies in kidney transplant recipients. , 2020, 8, e000908.		18
413	Rational Cancer Treatment Combinations: An Urgent Clinical Need. <i>Molecular Cell</i> , 2020, 78, 1002-1018.	4.5	95
414	Italian survey on managing immune checkpoint inhibitors in oncology during COVIDâ€™19 outbreak. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13315.	1.7	28
415	Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 595-610.	12.5	124
416	Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412. <i>Future Oncology</i> , 2020, 16, 1235-1243.	1.1	36
417	Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 4122-4130.	0.7	7
418	Targeted Therapy and Traditional Chemotherapy in Melanoma and Cutaneous Squamous Cell Carcinoma. <i>Facial Plastic Surgery</i> , 2020, 36, 186-193.	0.5	5
419	Real-World Recurrence Rates and Economic Burden in Patients with Resected Early-Stage Melanoma. <i>Dermatology and Therapy</i> , 2020, 10, 985-999.	1.4	6
420	Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors. , 2020, 8, e000665.		8

#	ARTICLE	IF	CITATIONS
421	Sentinel Lymph Node Biopsy for T1b Melanoma: Balancing Prognostic Value and Cost. <i>Annals of Surgical Oncology</i> , 2020, 27, 5248-5256.	0.7	12
422	Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF. <i>Frontiers in Immunology</i> , 2020, 11, 1147.	2.2	9
423	A New Hope. <i>Current Oncology</i> , 2020, 27, 41-42.	0.9	0
424	Spectrum and Clinical Activity of PD-1/PD-L1 Inhibitors: Regulatory Approval and Under Development. <i>Current Oncology Reports</i> , 2020, 22, 70.	1.8	11
425	Use of Immuno-Oncology in Melanoma. <i>Current Oncology</i> , 2020, 27, 51-58.	0.9	10
426	The Risk Ratio of Immune-Related Colitis, Hepatitis, and Pancreatitis in Patients With Solid Tumors Caused by PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 261.	1.3	11
427	Regulation of Cancer Immune Checkpoints. <i>Advances in Experimental Medicine and Biology</i> , 2020, , .	0.8	7
428	Sentinel Lymph Node Biopsy in Head and Neck Melanoma: Long-term Outcomes, Prognostic Value, Accuracy, and Safety. <i>Otolaryngology - Head and Neck Surgery</i> , 2020, 162, 520-529.	1.1	10
429	Immunotherapy, Inflammation and Colorectal Cancer. <i>Cells</i> , 2020, 9, 618.	1.8	167
430	International Multicenter Experience of Isolated Limb Infusion for In-Transit Melanoma Metastases in Octogenarian and Nonagenarian Patients. <i>Annals of Surgical Oncology</i> , 2020, 27, 1420-1429.	0.7	10
431	Regional nodal metastasis and 5-year survival in patients with thin melanoma in Queensland: a population-based study. <i>ANZ Journal of Surgery</i> , 2020, 90, 503-507.	0.3	3
432	Adjuvant therapies after curative treatments for hepatocellular carcinoma: Current status and prospects. <i>Genes and Diseases</i> , 2020, 7, 359-369.	1.5	40
433	Identifying challenges to implementation of clinical practice guidelines for sentinel lymph node biopsy in patients with melanoma in Australia: protocol paper for a mixed methods study. <i>BMJ Open</i> , 2020, 10, e032636.	0.8	6
434	Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study. <i>Frontiers in Oncology</i> , 2020, 10, 202.	1.3	6
435	Systemic Adjuvant Therapy for Adult Patients at High Risk for Recurrent Cutaneous or Mucosal Melanoma: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline. <i>Current Oncology</i> , 2020, 27, 43-52.	0.9	12
436	Use of immunotherapy and surgery for stage IV melanoma. <i>Cancer</i> , 2020, 126, 2614-2624.	2.0	14
437	Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram. <i>Journal of Clinical Oncology</i> , 2020, 38, 1591-1601.	0.8	50
438	Immune Checkpoint Inhibitor-Mediated Diarrhea and Colitis: A Clinical Review. <i>JCO Oncology Practice</i> , 2020, 16, 453-461.	1.4	42

#	ARTICLE	IF	CITATIONS
439	A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2589-2598.	2.0	44
440	The Role of Neoadjuvant Therapy in Melanoma. <i>Current Oncology Reports</i> , 2020, 22, 80.	1.8	8
441	Challenges in sentinel node pathology in the era of adjuvant treatment. <i>Journal of Surgical Oncology</i> , 2020, 122, 964-972.	0.8	7
442	Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination. <i>Oncolmmunology</i> , 2020, 9, 1738814.	2.1	13
443	Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand. <i>European Journal of Cancer</i> , 2020, 135, 211-220.	1.3	39
444	Adjuvant Therapy for Localized High-Risk Renal Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2020, 47, 345-358.	0.8	5
445	Article Commentary: Cancer Immunotherapy for the General Surgeon. <i>American Surgeon</i> , 2020, 86, 284-292.	0.4	0
446	Adjuvant Therapy for Cutaneous Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 455-465.	0.6	1
447	Immune Checkpoint Inhibition "Does It Cause Rheumatic Diseases? Mechanisms of Cancer-Associated Loss of Tolerance and Pathogenesis of Autoimmunity. <i>Rheumatic Disease Clinics of North America</i> , 2020, 46, 587-603.	0.8	3
448	Immunotherapy discontinuation "how, and when? Data from melanoma as a paradigm. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 707-715.	12.5	57
449	Adjuvant and neoadjuvant treatment of melanoma. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 301-305.	0.3	1
450	Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma. <i>Clinical Epigenetics</i> , 2020, 12, 94.	1.8	26
451	Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients. <i>Thoracic Cancer</i> , 2020, 11, 2406-2430.	0.8	40
452	20/20 in 2020: seeking clarity on the management of stage III melanoma in a rapidly changing treatment environment. <i>Annals of Translational Medicine</i> , 2020, 8, 776-776.	0.7	0
453	Circulating Tumor DNA Allows Early Treatment Monitoring in BRAF- and NRAS-Mutant Malignant Melanoma. <i>JCO Precision Oncology</i> , 2020, 4, 20-31.	1.5	19
454	The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis. <i>Journal of Biomedical Science</i> , 2020, 27, 77.	2.6	89
455	Orthopaedic Manifestations of Melanoma and Their Management. <i>Journal of the American Academy of Orthopaedic Surgeons</i> , The, 2020, 28, e540-e549.	1.1	1
456	Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer. <i>Seminars in Cancer Biology</i> , 2022, 79, 44-57.	4.3	104

#	ARTICLE	IF	CITATIONS
457	Fatal adverse events associated with programmed cell death protein 1 or programmed cell death-ligand 1 monotherapy in cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883591989575.	1.4	8
458	Neoadjuvant Immunotherapy for Locally Advanced Melanoma. <i>Current Treatment Options in Oncology</i> , 2020, 21, 10.	1.3	11
459	Immune-mediated adverse effects of immune-checkpoint inhibitors and their management in cancer. <i>Immunology Letters</i> , 2020, 221, 61-71.	1.1	12
460	It Is Time to Talk About Fertility and Immunotherapy. <i>Oncologist</i> , 2020, 25, 277-278.	1.9	42
461	A multidisciplinary expert opinion on CINV and RINV, unmet needs and practical real-life approaches. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 187-204.	1.0	5
462	An overview of binimetinib for the treatment of melanoma. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 747-754.	0.9	8
463	Immune checkpoint inhibitors in cancer treatment and potential effect modification by age. <i>Acta Oncologica</i> , 2020, 59, 247-248.	0.8	3
464	Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma. <i>Journal of the National Cancer Institute</i> , 2020, 112, 875-885.	3.0	20
465	Revisiting Immunotherapy: A Focus on Prostate Cancer. <i>Cancer Research</i> , 2020, 80, 1615-1623.	0.4	120
466	Intratumoral Immunotherapy for Early-stage Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 3091-3099.	3.2	88
467	Adjuvant pembrolizumab versus high-dose interferon γ -2b for Chinese patients with resected stage III melanoma: a retrospective cohort study. <i>Investigational New Drugs</i> , 2020, 38, 1334-1341.	1.2	10
468	Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy. <i>Frontiers in Molecular Biosciences</i> , 2019, 6, 160.	1.6	596
469	Radiotherapy and Immunotherapy for Cancer: From "Systemic" to "Multisite". <i>Clinical Cancer Research</i> , 2020, 26, 2777-2782.	3.2	103
470	Human Plasmacytoid Dendritic Cells and Cutaneous Melanoma. <i>Cells</i> , 2020, 9, 417.	1.8	32
471	The neutrophil-lymphocyte ratio and locoregional melanoma: a multicentre cohort study. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 559-568.	2.0	28
472	Anti-PD-1 and Novel Combinations in the Treatment of Melanoma—An Update. <i>Journal of Clinical Medicine</i> , 2020, 9, 223.	1.0	95
473	Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection. <i>International Journal of Molecular Sciences</i> , 2020, 21, 556.	1.8	21
474	Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1429-1441.	0.8	23

#	ARTICLE	IF	CITATIONS
475	Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy. <i>Molecular Cancer</i> , 2020, 19, 19.	7.9	180
476	Neoadjuvant checkpoint blockade for cancer immunotherapy. <i>Science</i> , 2020, 367, .	6.0	553
477	Homogeneous, Low-volume, Efficient, and Sensitive Quantitation of Circulating Exosomal PD-L1 for Cancer Diagnosis and Immunotherapy Response Prediction. <i>Angewandte Chemie</i> , 2020, 132, 4830-4835.	1.6	36
478	The role of cancer-derived microRNAs in cancer immune escape. <i>Journal of Hematology and Oncology</i> , 2020, 13, 25.	6.9	145
481	Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis. <i>European Journal of Cancer</i> , 2020, 131, 18-26.	1.3	50
482	Diagnostic value of 18F-FDG-PET to predict the tumour immune status defined by tumoural PD-L1 and CD8+tumour-infiltrating lymphocytes in oral squamous cell carcinoma. <i>British Journal of Cancer</i> , 2020, 122, 1686-1694.	2.9	38
483	Learning from clinical trials of neoadjuvant checkpoint blockade. <i>Nature Medicine</i> , 2020, 26, 475-484.	15.2	107
484	Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer. <i>Thyroid</i> , 2020, 30, 1458-1469.	2.4	44
485	Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce. , 2020, 8, e000398.		125
486	Neoadjuvant treatments in patients with high-risk resectable stage III/IV melanoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 403-413.	1.1	2
487	Treatment discontinuation and re-initiation of anti-PD-(L)1 agents in metastatic cancers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2153-2160.	1.2	8
488	Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. <i>BJU International</i> , 2020, 126, 73-82.	1.3	19
489	Targeted next generation sequencing (<sc>NGS</sc>) to classify melanocytic neoplasms. <i>Journal of Cutaneous Pathology</i> , 2020, 47, 691-704.	0.7	17
490	The Great Debate at "Melanoma Bridge", Naples, December 7th, 2019. <i>Journal of Translational Medicine</i> , 2020, 18, 171.	1.8	2
491	Adjuvant Therapy is Effective for Melanoma Patients with a Positive Sentinel Lymph Node Biopsy Who Forego Completion Lymphadenectomy. <i>Annals of Surgical Oncology</i> , 2020, 27, 5121-5125.	0.7	19
492	Systemic Therapy for Melanoma: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 3947-3970.	0.8	190
493	3D approaches to model the tumor microenvironment of pancreatic cancer. <i>Theranostics</i> , 2020, 10, 5074-5089.	4.6	74
494	Treatment of Advanced Melanoma in 2020 and Beyond. <i>Journal of Investigative Dermatology</i> , 2021, 141, 23-31.	0.3	193

#	ARTICLE	IF	CITATIONS
495	Single-agent temozolomide may be an effective option for late adjuvant therapy in patients with melanoma. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 40-45.	0.5	2
496	EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 36-48.	0.5	153
497	Consensus Guidelines for the Management of Melanoma during the COVID-19 Pandemic: Surgery, Systemic Anti-cancer Therapy, Radiotherapy and Follow-up. <i>Clinical Oncology</i> , 2021, 33, e54-e57.	0.6	19
498	Immunotherapy for advanced melanoma: current situation in Japan. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 3-9.	0.6	11
499	Immunotherapy for older patients with melanoma: From darkness to light?. <i>Pigment Cell and Melanoma Research</i> , 2021, 34, 550-563.	1.5	11
501	Systemic Anticancer Agents. , 2021, , 405-418.e3.		0
502	Efficacy of immune checkpoint inhibitors in different types of melanoma. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 4-13.	1.4	19
503	Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial. <i>European Radiology</i> , 2021, 31, 1853-1862.	2.3	10
504	What is the Cost-Effective Treatment for Melanoma Patients with a Positive Sentinel Node?. <i>Annals of Surgical Oncology</i> , 2021, 28, 2913-2922.	0.7	4
505	Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement. <i>American Journal of Transplantation</i> , 2021, 21, 475-483.	2.6	45
506	ASO Author Reflections: What is the Cost-Effective Treatment of Melanoma Patients with a Positive Sentinel Node?. <i>Annals of Surgical Oncology</i> , 2021, 28, 2923-2924.	0.7	1
507	Neoadjuvant immunotherapy for melanoma. <i>Journal of Surgical Oncology</i> , 2021, 123, 782-788.	0.8	26
508	Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. <i>British Journal of Cancer</i> , 2021, 124, 574-580.	2.9	27
509	Patients with Metastatic Melanoma Receiving Anticancer Drugs: Changes in Overall Survival, 2010â€”2017. <i>Journal of Investigative Dermatology</i> , 2021, 141, 830-839.e3.	0.3	10
510	Neoadjuvant immune checkpoint inhibitors in cancer, current state of the art. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103172.	2.0	8
511	Immune Checkpoint Therapies for Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 99-109.	0.9	4
512	Exploring the knowledge gap of immune checkpoint inhibitors in chronic renal failure: A systematic review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103169.	2.0	14
513	Prognostic significance of an 11-gene RNA assay in archival tissue of cutaneous melanoma stage Iâ€”III patients. <i>European Journal of Cancer</i> , 2021, 143, 11-18.	1.3	12

#	ARTICLE	IF	CITATIONS
514	Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administrationâ€™ Melanoma Research Alliance Public Workshop. <i>Clinical Cancer Research</i> , 2021, 27, 394-401.	3.2	5
515	A Multicenter Analysis of Immune Checkpoint Inhibitors as Adjuvant Therapy Following Treatment of Isolated Brain Metastasis. <i>Oncologist</i> , 2021, 26, e505-e507.	1.9	2
516	Knowledge and attitudes of Australian dermatologists towards sentinel lymph node biopsy for melanoma: a mixed methods study. <i>Australasian Journal of Dermatology</i> , 2021, 62, 168-176.	0.4	3
517	State of Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 1-27.	0.9	4
518	Adjuvant Therapy of Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 73-84.	0.9	2
519	Characterization of Sentinel Lymph Node Immune Signatures and Implications for Risk Stratification for Adjuvant Therapy in Melanoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 3501-3510.	0.7	13
520	Current status of immunotherapy for advanced gastric cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 20-27.	0.6	43
521	Adjuvant Radiation Therapy for Clinical Stage III Melanoma in the Modern Therapeutic Era. <i>Annals of Surgical Oncology</i> , 2021, 28, 3512-3521.	0.7	8
522	Comparative Efficacy and Safety of PD-1/PD-L1 Inhibitors for Patients with Solid Tumors: A Systematic Review and Bayesian Network Meta-analysis. <i>Journal of Cancer</i> , 2021, 12, 1133-1143.	1.2	14
523	Endocrine Adverse Events Caused by Different Types and Different Doses of Immune Checkpoint Inhibitors in the Treatment of Solid Tumors: A Metaâ€™Analysis and Systematic Review. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 282-297.	1.0	6
524	Medical Immunosuppression and Outcomes in Cutaneous Melanoma: A Population-Based Cohort Study. <i>Annals of Surgical Oncology</i> , 2021, 28, 3302-3311.	0.7	1
525	Applying adjuvant therapy for melanoma into clinical practice. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 129-133.	1.1	1
526	The role of sentinel lymph node status performed in melanoma patients with local recurrence or in transit metastasis. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1152-1156.	0.5	0
527	Biology of Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 29-56.	0.9	40
528	Sentinel lymph node biopsy is associated with increased cost in higher risk thin melanoma. <i>Journal of Surgical Oncology</i> , 2021, 123, 104-109.	0.8	3
529	Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma*. <i>British Journal of Dermatology</i> , 2021, 184, 944-951.	1.4	26
530	Is single versus combination therapy problematic in the treatment of cutaneous melanoma?. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 9-23.	1.3	5
531	Practical Management of Melanoma. , 2021, , 241-256.		0

#	ARTICLE	IF	CITATIONS
532	Immunotherapy-related pneumonitis and bacterial pneumonia after the successful treatment of metastatic malignant melanoma with pembrolizumab. <i>Medicine (United States)</i> , 2021, 100, e24018.	0.4	3
533	Pure and Mixed Desmoplastic Melanomas: A Retrospective Clinicopathologic Comparison of 33 Cases. <i>American Journal of Dermatopathology</i> , 2021, 43, 776-780.	0.3	3
534	miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors. <i>Pharmaceuticals</i> , 2021, 14, 89.	1.7	9
535	Challenges for NK cell-based therapies: What can we learn from lymph nodes?. , 2021, , 33-51.		0
536	Cancer of Unknown Primary: Challenges and Progress in Clinical Management. <i>Cancers</i> , 2021, 13, 451.	1.7	24
537	Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge"(December 4th-5th,) Tj	1.8	103784314
538	A Study on Fourteen Cases of Sinonasal Mucosal Malignant Melanoma. <i>Practica Otologica</i> , 2021, 114, 659-667.	0.0	0
539	Unusual severe gastritis and gastric ulcers caused by pembrolizumab. <i>Journal of Postgraduate Medicine</i> , 2022, 68, 38-40.	0.2	3
540	Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer. <i>Cancers</i> , 2021, 13, 131.	1.7	153
541	The Multiple Potential Biomarkers for Predicting Immunotherapy Response"Finding the Needle in the Haystack. <i>Cancers</i> , 2021, 13, 277.	1.7	16
543	Therapy understanding and health related quality of life in stage III/IV melanoma patients treated with novel adjuvant therapies. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 215-221.	0.4	5
544	Role of sentinel lymph node biopsy for cutaneous melanoma in elderly patients: preliminary results in a Latin-American population. <i>Ecancermedicalscience</i> , 2021, 15, 1167.	0.6	2
545	Pembrolizumab in Melanoma: From Care to Cure. , 2021, , 249-264.		1
546	Pathology of Melanoma and Skin Carcinomas. , 2021, , 3-30.		2
547	CTLA-4 blockade and interferon- γ induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma. <i>PLoS ONE</i> , 2021, 16, e0245287.	1.1	7
548	Ultraviolet radiation drives mutations in a subset of mucosal melanomas. <i>Nature Communications</i> , 2021, 12, 259.	5.8	27
549	Melanoom en andere huidtumoren. , 2021, , 515-526.		0
550	Indications and limits of postoperative radiotherapy for skin malignancies. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2021, 29, 100-106.	0.8	1

#	ARTICLE	IF	CITATIONS
551	Clinical Proteomics of Metastatic Melanoma Reveals Profiles of Organ Specificity and Treatment Resistance. <i>Clinical Cancer Research</i> , 2021, 27, 2074-2086.	3.2	12
552	Cancer Immunotherapy in Patients with Preexisting Inflammatory Arthritis. , 2021, , 273-291.		0
554	Conventional Radiological Techniques and PET-CT in Treatment Response Evaluation in Immunotherapy Settings. , 2021, , 83-99.		0
555	Nephrotoxicity in patients with solid tumors treated with anti-PD-1/PD-L1 monoclonal antibodies: a systematic review and meta-analysis. <i>Investigational New Drugs</i> , 2021, 39, 860-870.	1.2	12
556	Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis. <i>BMC Cancer</i> , 2021, 21, 3.	1.1	14
557	Neoadjuvant and Adjuvant Therapies of Melanoma. , 2021, , 401-415.		0
558	Activation of NF- κ B and p300/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	47
559	A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis. <i>Annals of Surgical Oncology</i> , 2021, 28, 6126-6137.	0.7	16
561	Clinical Practice Guideline on Melanoma From the Spanish Academy of Dermatology and Venereology (AEDV). <i>Actas Dermo-sifiliogrÁficas</i> , 2021, 112, 142-152.	0.2	2
562	Malignant Melanoma of the Gastrointestinal Tract: Symptoms, Diagnosis, and Current Treatment Options. <i>Cells</i> , 2021, 10, 327.	1.8	37
564	Pembrolizumab in the adjuvant treatment of melanoma: efficacy and safety. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 583-590.	1.1	4
565	Impact of Antiretroviral Therapy on Cancer Treatment Outcomes among People Living with HIV in Low- and Middle-Income Countries: a Systematic Review. <i>Current HIV/AIDS Reports</i> , 2021, 18, 105-116.	1.1	9
566	Adjuvant immunotherapy for melanoma. <i>Journal of Surgical Oncology</i> , 2021, 123, 789-797.	0.8	20
567	The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials. <i>Melanoma Research</i> , 2021, 31, 181-185.	0.6	14
568	Cost-Effectiveness of Pembrolizumab for the Adjuvant Treatment of Melanoma Patients with Lymph Node Involvement Who Have Undergone Complete Resection in Argentina. <i>Oncology and Therapy</i> , 2021, 9, 167-185.	1.0	3
569	Re-evaluation of Sentinel Lymph Node Biopsy for Melanoma. <i>Current Treatment Options in Oncology</i> , 2021, 22, 22.	1.3	16
570	Adjuvant Therapy of High-Risk (Stages IIcâ€“IV) Malignant Melanoma in the Post Interferon-Alpha Era: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 637161.	1.3	15
571	Associations of PD-L1, PD-L2, and HLA class I expression with responses to immunotherapy in patients with advanced sarcoma: post hoc analysis of a phase 1/2 trial. <i>Clinical and Translational Oncology</i> , 2021, 23, 1620-1629.	1.2	2

#	ARTICLE	IF	CITATIONS
572	Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). <i>Nature Medicine</i> , 2021, 27, 301-309.	15.2	218
573	Melanoma of unknown primary: New perspectives for an old story. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 158, 103208.	2.0	37
574	Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors. <i>British Journal of Dermatology</i> , 2021, 185, 263-271.	1.4	35
575	Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer. <i>ESMO Open</i> , 2021, 6, 100044.	2.0	15
576	Immune checkpoint inhibitors. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	27
577	ASO Author Reflections: The Tumor Lysate, Particle-Loaded, Dendritic Cell Vaccine for Advanced-Stage Melanoma: Reflection on Personalized Cancer Vaccination. <i>Annals of Surgical Oncology</i> , 2021, 28, 6138-6139.	0.7	1
578	Automated digital TIL analysis (ADTA) adds prognostic value to standard assessment of depth and ulceration in primary melanoma. <i>Scientific Reports</i> , 2021, 11, 2809.	1.6	20
579	DGKA Mediates Resistance to PD-1 Blockade. <i>Cancer Immunology Research</i> , 2021, 9, 371-385.	1.6	19
580	Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. <i>Nature Medicine</i> , 2021, 27, 256-263.	15.2	190
581	Considerations on the Role of Pembrolizumab Adjuvant Therapy in AJCC-8 Stage IIIA Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 943-944.	0.8	2
582	Multimarker scores of Th1 and Th2 immune cellular profiles in peripheral blood predict response and immune related toxicity with CTLA4 blockade and IFN γ in melanoma. <i>Translational Oncology</i> , 2021, 14, 101014.	1.7	13
583	Considerations for treatment duration in responders to immune checkpoint inhibitors. , 2021, 9, e001901.		69
584	Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2789-2800.	1.2	11
585	Melanoma cut \grave{a} neo. <i>Medicine</i> , 2021, 13, 1493-1505.	0.0	1
586	Long-term prognostic value of sentinel lymph node tumor burden in survival of melanoma patients. <i>Acta Oncol\acute{o}gica</i> , 2021, 60, 803-807.	0.8	4
587	Successful pembrolizumab treatment of microsatellite instability \hat{c} high intrahepatic cholangiocarcinoma: A case report. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, 2259-2263.	0.2	5
588	One-Year Morbidity Following Videoscopic Inguinal Lymphadenectomy for Stage III Melanoma. <i>Cancers</i> , 2021, 13, 1450.	1.7	2
589	Cerebral metastasis of Merkel cell carcinoma following resection with negative margins and adjuvant external beam radiation: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 118.	0.4	3

#	ARTICLE	IF	CITATIONS
590	Nodal Recurrence as Primary Driver of Early Relapse in Patients with SLN-Positive Melanoma: What Does It Mean for Providers and Patients?. <i>Annals of Surgical Oncology</i> , 2021, 28, 3452-3454.	0.7	0
591	Identification ACTA2 and KDR as key proteins for prognosis of PD-1/PD-L1 blockade therapy in melanoma. <i>Animal Models and Experimental Medicine</i> , 2021, 4, 138-150.	1.3	4
592	Macrophages and microglia: the cerberus of glioblastoma. <i>Acta Neuropathologica Communications</i> , 2021, 9, 54.	2.4	99
593	Should I Have Adjuvant Immunotherapy? An Interview Study Among Adults with Resected Stage 3 Melanoma and Their Partners. <i>Patient</i> , 2021, 14, 635-647.	1.1	8
594	Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma. <i>Cancers</i> , 2021, 13, 1383.	1.7	120
595	Primary malignant melanoma of uterine cervix treated with pembrolizumab as adjuvant immunotherapy. <i>International Cancer Conference Journal</i> , 2021, 10, 254-258.	0.2	3
596	Expression of Potential Targets for Cell-Based Therapies on Melanoma Cells. <i>Life</i> , 2021, 11, 269.	1.1	7
597	A review of the AJCC melanoma staging system in the TNM classification (eighth edition). <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 671-674.	0.6	8
598	Pembrolizumab Utilization and Clinical Outcomes Among Patients With Advanced Melanoma in the US Community Oncology Setting: An Updated Analysis. <i>Journal of Immunotherapy</i> , 2021, 44, 224-233.	1.2	3
599	Cutaneous melanoma: cost of illness under Brazilian health system perspectives. <i>BMC Health Services Research</i> , 2021, 21, 284.	0.9	6
600	Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	84
601	Drug-Related Pneumonitis in Cancer Treatment during the COVID-19 Era. <i>Cancers</i> , 2021, 13, 1052.	1.7	5
602	BRAF Gene and Melanoma: Back to the Future. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3474.	1.8	40
603	Sentinel node biopsy for primary cutaneous melanoma. <i>Annals of Oncology</i> , 2021, 32, 290-292.	0.6	8
604	SEOM clinical guideline for the management of cutaneous melanoma (2020). <i>Clinical and Translational Oncology</i> , 2021, 23, 948-960.	1.2	22
605	Reply to E. Hindi. <i>Journal of Clinical Oncology</i> , 2021, 39, 944-946.	0.8	1
606	Emerging PD-1/PD-L1 antagonists for the treatment of malignant melanoma. <i>Expert Opinion on Emerging Drugs</i> , 2021, 26, 79-92.	1.0	13
607	Recent advancements in melanoma management. <i>Internal Medicine Journal</i> , 2021, 51, 327-333.	0.5	4

#	ARTICLE	IF	CITATIONS
608	Neoadjuvant Cyoreductive Treatment With BRAF/MEK Inhibition of Prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR. <i>Annals of Surgery</i> , 2021, 274, 383-389.	2.1	28
609	Radiation Therapy for Cutaneous Malignancies of the Head and Neck. <i>Otolaryngologic Clinics of North America</i> , 2021, 54, 307-327.	0.5	1
610	Overview of Subcutaneous Metastatic Melanoma. <i>Cancers</i> , 2021, 13, 2063.	1.7	0
611	Synergistic Activation of Antitumor Immunity by a Particulate Therapeutic Vaccine. <i>Advanced Science</i> , 2021, 8, 2100166.	5.6	18
612	Tumor-infiltrating lymphocytes are associated with improved survival in node-positive Merkel cell carcinoma: A national cohort analysis. <i>Journal of the American Academy of Dermatology</i> , 2021, , .	0.6	2
613	Contemporary Neoadjuvant Therapies for High-Risk Melanoma: A Systematic Review. <i>Cancers</i> , 2021, 13, 1905.	1.7	7
614	Molecular Biomarkers for Melanoma Screening, Diagnosis and Prognosis: Current State and Future Prospects. <i>Frontiers in Medicine</i> , 2021, 8, 642380.	1.2	28
615	Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-II). <i>Cancer</i> , 2021, 127, 2251-2261.	2.0	37
616	Metastasis-Initiating Cells and Ecosystems. <i>Cancer Discovery</i> , 2021, 11, 971-994.	7.7	134
617	PTEN loss correlates with T cell exclusion across human cancers. <i>BMC Cancer</i> , 2021, 21, 429.	1.1	38
618	Hematological immune related adverse events after treatment with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2021, 147, 170-181.	1.3	40
619	Find the Flame: Predictive Biomarkers for Immunotherapy in Melanoma. <i>Cancers</i> , 2021, 13, 1819.	1.7	16
620	The Next Decade of Immune Checkpoint Therapy. <i>Cancer Discovery</i> , 2021, 11, 838-857.	7.7	363
621	Identification of 15 lncRNAs Signature for Predicting Survival Benefit of Advanced Melanoma Patients Treated with Anti-PD-1 Monotherapy. <i>Cells</i> , 2021, 10, 977.	1.8	25
622	Endocrine toxicities of immune checkpoint inhibitors. <i>Nature Reviews Endocrinology</i> , 2021, 17, 389-399.	4.3	162
623	Evaluation of treatment, prognostic factors, and survival in 198 vulvar melanoma patients: Implications for clinical practice. <i>Gynecologic Oncology</i> , 2021, 161, 202-210.	0.6	8
624	Active surveillance of patients who have melanoma with a positive sentinel node in an era of effective adjuvant therapy: Early lessons learned and still learning. <i>Cancer</i> , 2021, 127, 2177-2180.	2.0	1
625	A Pilot Study of Short-course Nivolumab and Low-dose Ipilimumab for Adjuvant Treatment of Melanoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 254-257.	0.6	2

#	ARTICLE	IF	CITATIONS
626	Nodal Recurrence is a Primary Driver of Early Relapse for Patients with Sentinel Lymph Node-Positive Melanoma in the Modern Therapeutic Era. <i>Annals of Surgical Oncology</i> , 2021, 28, 3480-3489.	0.7	7
627	Immune Checkpoint Inhibitor Associated Hepatotoxicity in Primary Liver Cancer Versus Other Cancers: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 650292.	1.3	22
628	Tumour draining lymph node-generated CD8 T cells play a role in controlling lung metastases after a primary tumour is removed but not when adjuvant immunotherapy is used. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3249-3258.	2.0	14
629	Single or dual immune checkpoint inhibitor as adjuvant therapy in advanced melanoma. <i>European Journal of Cancer</i> , 2021, 147, 140-141.	1.3	0
630	Looking into a Better Future: Novel Therapies for Metastatic Melanoma. <i>Dermatology and Therapy</i> , 2021, 11, 751-767.	1.4	17
631	Immune checkpoint inhibitors in adjuvant setting after radical resection of melanoma: a meta-analysis of the pivotal trials. <i>Human Vaccines and Immunotherapeutics</i> , 2021, , 1-6.	1.4	3
632	The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020. <i>Journal of Translational Medicine</i> , 2021, 19, 142.	1.8	1
633	Prognostic and Predictive Biomarkers in Stage III Melanoma: Current Insights and Clinical Implications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4561.	1.8	21
634	The regulation of immune checkpoints by the hypoxic tumor microenvironment. <i>PeerJ</i> , 2021, 9, e11306.	0.9	22
635	Adjuvant pembrolizumab for melanoma: update from the EORTC 1325-MG/KEYNOTE-054 trial. <i>Lancet Oncology</i> , The, 2021, 22, 573-575.	5.1	7
636	Surgery of small bowel melanoma metastases in the era of efficient medical therapies. <i>Melanoma Research</i> , 2021, Publish Ahead of Print, 358-365.	0.6	2
637	Proposed quality performance indicators of sentinel lymph node biopsy for cutaneous melanoma. <i>ANZ Journal of Surgery</i> , 2021, , .	0.3	1
638	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 655-664.	5.1	37
639	Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma. <i>JAMA Oncology</i> , 2021, 7, 744.	3.4	110
640	Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time?. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 511-522.	3.3	6
641	Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review. <i>Frontiers in Oncology</i> , 2021, 11, 621639.	1.3	12
642	Identification of inhibitory immune checkpoints and relevant regulatory pathways in breast cancer stem cells. <i>Cancer Medicine</i> , 2021, 10, 3794-3807.	1.3	8
643	The Proportion Cured of Patients with Resected Stage II-III Cutaneous Melanoma in Sweden. <i>Cancers</i> , 2021, 13, 2456.	1.7	2

#	ARTICLE	IF	CITATIONS
644	Adjuvant pembrolizumab in genomically selected high-risk patients with muscle-invasive bladder cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2021, , 107815522110165.	0.5	2
645	High discordance rate in assessing sentinel node positivity in cutaneous melanoma: Expert review may reduce unjustified adjuvant treatment. <i>European Journal of Cancer</i> , 2021, 149, 105-113.	1.3	4
646	Sequential immunotherapy in melanoma. <i>Melanoma Research</i> , 2021, Publish Ahead of Print, 366-370.	0.6	3
647	Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma. <i>European Journal of Cancer</i> , 2021, 148, 51-57.	1.3	16
648	Melanoma models for the next generation of therapies. <i>Cancer Cell</i> , 2021, 39, 610-631.	7.7	90
649	Detection of cancer metastasis: past, present and future. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 21-28.	1.7	9
650	Assessment of the Clinical Trials Safety Profile of PD-1/PD-L1 Inhibitors Among Patients With Cancer: An Updated Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 662392.	1.3	3
651	Exceptional Response to Pembrolizumab and Trastuzumab in a Heavily Pretreated Patient With HER2-Positive TMB-H and MSI-H Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 904-909.	1.5	1
652	Efficacy of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9578-9578.	0.8	1
653	C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting. <i>Melanoma Research</i> , 2021, 31, 371-377.	0.6	12
654	Chemotherapy in focus: A meta-analysis confronts immunotherapy in the treatment of advanced melanoma. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 161, 103304.	2.0	3
655	Systemic Therapy for Head and Neck Skin Cancers. <i>Face</i> , 2021, 2, 121-130.	0.1	0
656	The Role of Clinical Prediction Tools to Risk Stratify Patients with Melanoma After a Positive Sentinel Lymph Node Biopsy. <i>Annals of Surgical Oncology</i> , 2021, 28, 4082-4083.	0.7	4
657	The role of regional chemotherapy for advanced limb melanoma in the era of potentially effective systemic therapies. <i>Melanoma Research</i> , 2021, Publish Ahead of Print, 290-297.	0.6	2
658	Current management of melanoma patients with nodal metastases. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 181-199.	1.7	8
659	Metabolic Interplay between the Immune System and Melanoma Cells: Therapeutic Implications. <i>Biomedicines</i> , 2021, 9, 607.	1.4	12
660	Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients. <i>Cancers</i> , 2021, 13, 2319.	1.7	15
661	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 643-654.	5.1	224

#	ARTICLE	IF	CITATIONS
662	Identifying High-Risk Tumors within AJCC Stage IB–III Melanomas Using a Seven-Marker Immunohistochemical Signature. <i>Cancers</i> , 2021, 13, 2902.	1.7	6
663	Immune Checkpoint Inhibitors-Related Thyroid Dysfunction: Epidemiology, Clinical Presentation, Possible Pathogenesis, and Management. <i>Frontiers in Endocrinology</i> , 2021, 12, 649863.	1.5	24
664	Drug-induced sarcoidosis-like reactions. <i>Current Opinion in Pulmonary Medicine</i> , 2021, 27, 439-447.	1.2	20
665	Recent Advances in the Treatment of Melanoma. <i>New England Journal of Medicine</i> , 2021, 384, 2229-2240.	13.9	201
666	Vitamin D Supplementation Regulates Postoperative Serum Levels of PD-L1 in Patients with Digestive Tract Cancer and Improves Survivals in the Highest Quintile of PD-L1: A Post Hoc Analysis of the AMATERASU Randomized Controlled Trial. <i>Nutrients</i> , 2021, 13, 1987.	1.7	16
667	Approaches for Handling Immunopathological and Clinical Data Using Deep Learning Methodology: Multiplex IHC/IF Data as a Paradigm. , 0, , .		0
668	Pseudoprogression with Neoadjuvant Immunotherapy for Cutaneous Melanoma. <i>Case Reports in Oncology</i> , 2021, 14, 881-885.	0.3	1
669	Vulvar Melanoma: Molecular Characteristics, Diagnosis, Surgical Management, and Medical Treatment. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 639-651.	3.3	15
670	Adjuvant therapy in renal cell carcinoma: Current knowledges and future perspectives. <i>Cancer Treatment Reviews</i> , 2021, 97, 102207.	3.4	35
671	Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer. <i>EMBO Molecular Medicine</i> , 2021, 13, e08253.	3.3	18
672	Prior Therapy With Pegylated-Interferon Alfa-2b Improves the Efficacy of Adjuvant Pembrolizumab in Resectable Advanced Melanoma. <i>Frontiers in Oncology</i> , 2021, 11, 675873.	1.3	7
673	The dark side of immunotherapy. <i>Annals of Translational Medicine</i> , 2021, 9, 1041-1041.	0.7	12
674	Prognostic impact of thyroid dysfunctions on progression-free survival in patients with metastatic melanoma treated with anti-PD-1 antibodies. <i>Melanoma Research</i> , 2021, 31, 208-217.	0.6	8
675	High membrane expression of CMTM6 in hepatocellular carcinoma is associated with tumor recurrence. <i>Cancer Science</i> , 2021, 112, 3314-3323.	1.7	15
676	Multidisciplinary Care of BRAF-Mutant Stage III Melanoma: A Physicians Perspective Review. <i>Oncologist</i> , 2021, 26, e1644-e1651.	1.9	5
678	How we treat locoregional melanoma. <i>ESMO Open</i> , 2021, 6, 100136.	2.0	10
679	Cutaneous melanoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28992.	0.8	9
680	Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 518.	1.1	8

#	ARTICLE	IF	CITATIONS
681	Anticancer innovative therapy congress: Highlights from the 10th anniversary edition. Cytokine and Growth Factor Reviews, 2021, 59, 1-8.	3.2	4
682	Risk tolerance in adjuvant and metastatic melanoma settings: a patient perspective study using the threshold technique. Future Oncology, 2021, 17, 2151-2167.	1.1	4
683	The effect of adding immune checkpoint inhibitors on the risk of pneumonitis for solid tumours: a meta-analysis of phase III randomised controlled trials. European Journal of Cancer, 2021, 150, 168-178.	1.3	11
684	Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. Lancet Oncology, The, 2021, 22, 836-847.	5.1	104
685	First line immunotherapy extends brain metastasis free survival, improves overall survival, and reduces the incidence of brain metastasis in patients with advanced melanoma. Cancer Reports, 2021, 4, e1419.	0.6	4
686	Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy. Frontiers in Oncology, 2021, 11, 670726.	1.3	26
687	Frequency, Treatment and Outcome of Immune-Related Toxicities in Patients with Immune-Checkpoint Inhibitors for Advanced Melanoma: Results from an Institutional Database Analysis. Cancers, 2021, 13, 2931.	1.7	19
688	Impact of the development of immune related adverse events in metastatic melanoma treated with PD -1 inhibitors. Melanoma Research, 2021, 31, 258-263.	0.6	9
689	A Solitary Melanoma Metastasis Confined to the Submandibular Gland. Case Reports in Oncology, 2021, 14, 957-962.	0.3	2
690	A Case Series of Multiple Primary Malignancies Among Patients With Advanced Melanoma. Cureus, 2021, 13, e15480.	0.2	2
691	Adjuvant versus Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: Clinical and Immunologic Perspectives. Seminars in Liver Disease, 2021, 41, 263-276.	1.8	14
692	Indocyanine Green Fluorescence Imaging with Lymphoscintigraphy Improves the Accuracy of Sentinel Lymph Node Biopsy in Melanoma. Plastic and Reconstructive Surgery, 2021, 148, 83e-93e.	0.7	1
693	Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients. Annals of Surgical Oncology, 2021, 28, 9039-9047.	0.7	4
694	Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma. Annals of Oncology, 2021, 32, 766-777.	0.6	22
695	A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation. Journal of Experimental and Clinical Cancer Research, 2021, 40, 240.	3.5	3
696	Predictive factors of neoadjuvant immune checkpoint blockade in melanoma. Human Vaccines and Immunotherapeutics, 2022, 18, 1-9.	1.4	3
697	Novel adjuvant options for cutaneous melanoma. Annals of Oncology, 2021, 32, 854-865.	0.6	31
698	Male fertility during and after immune checkpoint inhibitor therapy: A cross-sectional pilot study. European Journal of Cancer, 2021, 152, 41-48.	1.3	18

#	ARTICLE	IF	CITATIONS
699	Current Landscape and Open Questions on Adjuvant Therapies in Melanoma. <i>Dermatology Practical and Conceptual</i> , 2021, 11, 2021165S.	0.5	0
700	Histological regression in melanoma: impact on sentinel lymph node status and survival. <i>Modern Pathology</i> , 2021, 34, 1999-2008.	2.9	16
701	Cutaneous adverse events associated with immune checkpoint blockade: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103376.	2.0	9
702	Immunotherapy in Older Adults With Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2115-2127.	0.8	33
703	Advances in the discovery and development of melanoma drug therapies. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 1319-1347.	2.5	9
704	Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials. <i>Frontiers in Pharmacology</i> , 2021, 12, 640099.	1.6	3
705	Cancer Stemness Associated With Prognosis and the Efficacy of Immunotherapy in Adrenocortical Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 651622.	1.3	17
706	Rheumatic and musculoskeletal disorders induced by immune checkpoint inhibitors: Consequences on overall survival. <i>Joint Bone Spine</i> , 2021, 88, 105168.	0.8	6
707	Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!. <i>European Journal of Cancer</i> , 2021, 152, 155-164.	1.3	21
708	Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 3738.	1.7	7
709	Adjuvant anti-PD-1 inhibitor versus high-dose interferon γ for Chinese patients with cutaneous and acral melanoma: A retrospective cohort analysis. <i>Dermatologic Therapy</i> , 2021, 34, e15067.	0.8	6
710	FOXA1 overexpression suppresses interferon signaling and immune response in cancer. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	48
711	Design and Encapsulation of Immunomodulators onto Gold Nanoparticles in Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8037.	1.8	17
712	Adjuvant anti-PD-1 antibody treatment in stage III/IV melanoma: real-world experience and health economic considerations. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1186-1198.	0.4	3
713	Melanoma and Sarcoidosis in Patients Receiving or Not Antineoplastic Therapy. <i>Case Reports in Oncology</i> , 2021, 14, 1059-1065.	0.3	2
714	Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapy. <i>ANZ Journal of Surgery</i> , 2021, 91, 3-13.	0.3	7
715	The Risk of Immune-Related Thyroid Dysfunction Induced by PD-1/PD-L1 Inhibitors in Cancer Patients: An Updated Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 667650.	1.3	8
716	Serum Troponin T Concentrations Are Frequently Elevated in Advanced Skin Cancer Patients Prior to Immune Checkpoint Inhibitor Therapy: Experience From a Single Tertiary Referral Center. <i>Frontiers in Medicine</i> , 2021, 8, 691618.	1.2	4

#	ARTICLE	IF	CITATIONS
717	New systemic therapies for cutaneous melanoma: why, who and what. <i>Italian Journal of Dermatology and Venereology</i> , 2021, 156, 344-355.	0.1	2
718	Malignant melanoma: evolving practice management in an era of increasingly effective systemic therapies. <i>Current Problems in Surgery</i> , 2022, 59, 101030.	0.6	4
719	Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health. <i>Oncologist</i> , 2021, 26, e1786-e1799.	1.9	52
720	Association of Adjuvant Immunotherapy Duration With Chronic Immune-Related Adverse Events. <i>JAMA Oncology</i> , 2021, 7, 1573-1574.	3.4	1
721	Proposed Quality Performance Indicators (QPI's) for axillary lymphadenectomy in metastatic cutaneous melanoma. <i>European Journal of Surgical Oncology</i> , 2021, 47, 3011-3019.	0.5	1
722	Novel insights on gut microbiota manipulation and immune checkpoint inhibition in cancer (Review). <i>International Journal of Oncology</i> , 2021, 59, .	1.4	17
723	Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis. <i>PLoS ONE</i> , 2021, 16, e0255716.	1.1	17
724	Fucoidan-Supplemented Diet Potentiates Immune Checkpoint Blockage by Enhancing Antitumor Immunity. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 733246.	1.8	12
725	Multifunctional Nanocarriers-Mediated Synergistic Combination of Immune Checkpoint Inhibitor Cancer Immunotherapy and Interventional Oncology Therapy. <i>Advanced NanoBiomed Research</i> , 2021, 1, 2100010.	1.7	5
726	Prognostic significance of T cells, PD-L1 immune checkpoint and tumour associated macrophages in clear cell carcinoma of the ovary. <i>Gynecologic Oncology</i> , 2021, 162, 421-430.	0.6	10
727	COVID-19 vaccination mimicking lymph-node progression in a patient with melanoma: a case report. <i>Melanoma Research</i> , 2021, 31, 490-493.	0.6	6
728	Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2656-2666.	0.8	145
730	Faecal microbiota transplantation enhances efficacy of immune checkpoint inhibitors therapy against cancer. <i>World Journal of Gastroenterology</i> , 2021, 27, 5362-5375.	1.4	17
731	Surveillance of Sentinel Node-Positive Melanoma Patients Who Receive Adjuvant Therapy Without Undergoing Completion Lymph Node Dissection. <i>Annals of Surgical Oncology</i> , 2021, 28, 6978-6985.	0.7	13
732	Tratamiento quirúrgico ganglionar regional en los pacientes con melanoma primario localizado y biopsia de ganglio centinela positivo: Conducta clínica en el Instituto Nacional de Cancerología, Colombia. <i>Revista Colombiana De Cancerología</i> , 0, 25, 167-163.	0.0	0
733	Current landscape of immunotherapy trials in locally advanced and high-risk head and neck cancer. <i>Immunotherapy</i> , 2021, 13, 931-940.	1.0	1
734	Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021, 385, 683-694.	13.9	394
735	Immune checkpoint inhibitor-related hepatotoxicity: A review. <i>World Journal of Gastroenterology</i> , 2021, 27, 5376-5391.	1.4	52

#	ARTICLE	IF	CITATIONS
736	Immunotherapy for Non-melanoma Skin Cancer. <i>Current Oncology Reports</i> , 2021, 23, 125.	1.8	49
737	Current Trends of Immunotherapy in the Treatment of Cutaneous Melanoma: A Review. <i>Dermatology and Therapy</i> , 2021, 11, 1481-1496.	1.4	12
738	The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients. <i>European Journal of Cancer</i> , 2021, 155, 268-280.	1.3	37
739	Adjuvant Therapy for Stage III Melanoma Without Immediate Completion Lymph Node Dissection. <i>Annals of Surgical Oncology</i> , 2022, 29, 806-815.	0.7	7
740	Immune Responses Following Locoregional Treatment for Hepatocellular Carcinoma: Possible Roles of Adjuvant Immunotherapy. <i>Pharmaceutics</i> , 2021, 13, 1387.	2.0	18
741	First line treatment of BRAF mutated advanced melanoma: Does one size fit all?. <i>Cancer Treatment Reviews</i> , 2021, 99, 102253.	3.4	26
742	Establishment and Validation of a Genetic Label Associated With M2 Macrophage Infiltration to Predict Survival in Patients With Colon Cancer and to Assist in Immunotherapy. <i>Frontiers in Genetics</i> , 2021, 12, 726387.	1.1	5
743	Adjuvant PD-L1 blockade in non-small-cell lung cancer. <i>Lancet, The</i> , 2021, 398, 1281-1283.	6.3	4
744	Outcomes for systemic therapy in older patients with metastatic melanoma: Results from the Dutch Melanoma Treatment Registry. <i>Journal of Geriatric Oncology</i> , 2021, 12, 1031-1038.	0.5	2
745	BRAF mutation correlates with worse local/regional control following radiation therapy in patients with stage III melanoma. <i>Radiation Oncology</i> , 2021, 16, 181.	1.2	5
746	Three Cases of Anorectal Malignant Melanoma Treated with Laparoscopic Abdominoperineal Resection. <i>Japanese Journal of Gastroenterological Surgery</i> , 2021, 54, 644-656.	0.0	0
747	The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges. <i>Targeted Oncology</i> , 2021, 16, 537-552.	1.7	20
748	Therapeutic neck dissection in head and neck melanoma patients: Comparing extent of surgery and clinical outcome in two cohorts. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2454-2459.	0.5	0
749	Development and Validation of a Modified Pathologic Nodal Classification System for Cutaneous Melanoma. <i>JAMA Surgery</i> , 2021, 156, e214298.	2.2	1
750	Usage Patterns and Incidence of Thyroid-related Adverse Events in Patients Treated with PD-1 Inhibitors. <i>Korean Journal of Clinical Pharmacy</i> , 2021, 31, 188-197.	0.0	0
751	Adjuvant treatment for melanoma in clinical practice – Trial versus reality. <i>European Journal of Cancer</i> , 2021, 158, 234-245.	1.3	12
752	Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma. <i>Frontiers in Oncology</i> , 2021, 11, 741993.	1.3	9
753	Which adjuvant treatment for patients with BRAFV600-mutant cutaneous melanoma?. <i>Annales De Dermatologie Et De Venereologie</i> , 2021, 148, 145-155.	0.5	4

#	ARTICLE	IF	CITATIONS
754	Results of isolated limb perfusion for metastasized malignant melanoma. <i>Surgical Oncology</i> , 2021, 38, 101603.	0.8	1
755	Impact of the changes in the completion lymph node dissection criteria and approval of adjuvant therapies on the real-world outcomes of Japanese stage III melanoma patients. <i>International Journal of Clinical Oncology</i> , 2021, 26, 2338-2346.	1.0	3
756	Immune checkpoint inhibitors in melanoma. <i>Lancet, The</i> , 2021, 398, 1002-1014.	6.3	462
757	Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews. <i>BMC Cancer</i> , 2021, 21, 1014.	1.1	3
758	Fertility preservation and management of pregnancy in melanoma patients requiring systemic therapy. <i>ESMO Open</i> , 2021, 6, 100248.	2.0	10
759	Adjuvant and Neoadjuvant Therapeutics for the Treatment of Cutaneous Melanoma. <i>Clinics in Plastic Surgery</i> , 2021, 48, 651-658.	0.7	5
760	Emerging Therapies in the Treatment of Advanced Melanoma. <i>Clinics in Plastic Surgery</i> , 2021, 48, 713-733.	0.7	3
761	Mathematical modeling approach of cancer immunoediting reveals new insights in targeted-therapy and timing plan of cancer treatment. <i>Chaos, Solitons and Fractals</i> , 2021, 152, 111349.	2.5	3
762	Adjuvant treatment in patients with melanoma: The planning of scanning. <i>European Journal of Cancer</i> , 2021, 157, 306-307.	1.3	1
763	Is there a Role for Adjuvant Targeted and Immunotherapies in Patients with Locoregionally-Advanced Head and Neck Cancer?. , 2021, , 205-219.		1
764	TLRs as a Promise Target Along With Immune Checkpoint Against Gastric Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 611444.	1.8	24
765	Role of immunotherapy in stage IIIA non-small cell lung cancer: a narrative review. <i>Current Challenges in Thoracic Surgery</i> , 0, .	0.2	2
766	Targeting metastatic cancer. <i>Nature Medicine</i> , 2021, 27, 34-44.	15.2	447
767	Lymphadenectomy after a positive sentinel node biopsy in patients with cutaneous melanoma. A systematic review. <i>Surgical and Experimental Pathology</i> , 2021, 4, .	0.2	0
768	Rheumatic immune-related adverse events associated with immune checkpoint inhibitors compared with placebo in oncologic patients: a systemic review and meta-analysis. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232097699.	1.1	12
769	A case of amelanotic melanoma in the maxillary gingiva. <i>Journal of Japanese Society of Oral Oncology</i> , 2021, 33, 61-68.	0.0	0
770	Ulcerated Lichen Planus after Adjuvant Use of Programmed Cell Death-1-Inhibitor: A Case Report and Systematic Review of the Literature. <i>Acta Dermato-Venereologica</i> , 2021, 101, adv00472.	0.6	8
771	A multicenter characterization of hepatitis associated with immune checkpoint inhibitors. <i>Oncolimmunology</i> , 2021, 10, 1875639.	2.1	30

#	ARTICLE	IF	CITATIONS
772	Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 25-31.	1.0	12
773	Metastasectomy for melanoma is associated with improved overall survival in responders to targeted molecular or immunotherapy. <i>Journal of Surgical Oncology</i> , 2020, 122, 555-561.	0.8	8
774	Surgical Management of Distant Melanoma Metastases. , 2020, , 1359-1402.		1
775	Neoadjuvant Systemic Therapy for High-Risk Melanoma Patients. , 2020, , 767-793.		1
776	The Era of Checkpoint Inhibition: Lessons Learned from Melanoma. <i>Recent Results in Cancer Research</i> , 2020, 214, 169-187.	1.8	7
778	Immunotherapy for Melanoma. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 51-68.	0.8	41
779	Sequencing and Combinations of Molecularly Targeted and Immunotherapy for BRAF-Mutant Melanoma. , 2019, , 1-27.		1
780	Therapeutic Development of Immune Checkpoint Inhibitors. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 619-649.	0.8	15
781	The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer. <i>BioDrugs</i> , 2020, 34, 495-503.	2.2	15
782	Immune checkpoint inhibitors to treat cutaneous malignancies. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1239-1253.	0.6	56
783	Toxicities from immunotherapy: From clinical trials to real-world clinical practice. <i>Medicina Clínica</i> , 2020, 155, 541-547.	0.3	8
784	Age and Melanocytic Lesions. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 369-386.	0.6	1
785	Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 358-372.	5.1	94
786	Checkpoint inhibitor immunotherapy in kidney cancer. <i>Nature Reviews Urology</i> , 2020, 17, 137-150.	1.9	162
787	Correlation between patients' age and cancer immunotherapy efficacy. <i>Oncolmmunology</i> , 2019, 8, e1568810.	2.1	44
788	Safety of Immunotherapy Rechallenge After Immune-related Adverse Events in Patients With Advanced Cancer. <i>Journal of Immunotherapy</i> , 2021, 44, 41-48.	1.2	13
789	Single-center real-life experience with low-dose ipilimumab monotherapy in adjuvant setting for patients with stage III melanoma. <i>Melanoma Research</i> , 2019, 29, 648-654.	0.6	8
790	Identification of prognostic mRNAs in metastatic cutaneous melanoma. <i>Melanoma Research</i> , 2020, 30, 543-547.	0.6	7

#	ARTICLE	IF	CITATIONS
791	PD-1 inhibitors might limit the development of brain metastases in patients with advanced melanoma. <i>Melanoma Research</i> , 2020, 30, 580-589.	0.6	4
794	Uptake of positron emission tomography tracers reflects the tumor immune status in esophageal squamous cell carcinoma. <i>Cancer Science</i> , 2020, 111, 1969-1978.	1.7	13
795	Circulating Tumor Cells and Early Relapse in Node-positive Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 1886-1895.	3.2	42
796	Cellular therapy against public neoantigens. <i>Journal of Clinical Investigation</i> , 2019, 129, 506-508.	3.9	8
797	Time to dissect the autoimmune etiology of cancer antibody immunotherapy. <i>Journal of Clinical Investigation</i> , 2020, 130, 51-61.	3.9	66
798	Undifferentiated carcinoma of the transverse colon with rhabdoid features that developed during treatment of non-small cell lung carcinoma with pembrolizumab: a case report. <i>Surgical Case Reports</i> , 2020, 6, 196.	0.2	3
799	Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. <i>European Journal of Endocrinology</i> , 2019, 181, 211-219.	1.9	116
800	Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors. , 2019, 2, 744-761.		3
801	Cancer burden in the United States—a review. <i>Annals of Cancer Epidemiology</i> , 0, 1, 1-1.	1.8	5
802	Evolution of Molecular Targets in Melanoma Treatment. <i>Current Pharmaceutical Design</i> , 2020, 26, 396-414.	0.9	10
803	Biomarkers Predicting for Response and Relapse with Melanoma Systemic Therapy. <i>Acta Dermato-Venereologica</i> , 2020, 100, adv00142.	0.6	3
804	Management of cutaneous melanoma: comparison of the leading international guidelines updated to the 8th American Joint Committee on Cancer staging system and workup proposal by the Italian Society of Dermatology. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 126-145.	0.8	5
805	A Case of Non-small-cell Lung Cancer with Acute Optic Neuritis Observed After Pembrolizumab Treatment. <i>Japanese Journal of Lung Cancer</i> , 2020, 60, 385-389.	0.0	1
806	Immune Response Checkpoint Inhibitors: New Risks of a New Class of Antitumor Agents. <i>Safety and Risk of Pharmacotherapy</i> , 2020, 8, 9-22.	0.1	10
807	The Systemic Treatment of Melanoma: The Place of Immune Checkpoint Inhibitors and the Suppression of Intracellular Signal Transduction. <i>Deutsches &#x0308;rzteblatt International</i> , 2019, 116, 497-504.	0.6	15
808	Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies. <i>Antibodies</i> , 2020, 9, 17.	1.2	14
809	Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. <i>Cancers</i> , 2020, 12, 1303.	1.7	6
810	Mechanistic insight of predictive biomarkers for antitumor PD/PDL1 blockade: A paradigm shift towards immunome evaluation (Review). <i>Oncology Reports</i> , 2020, 44, 424-437.	1.2	18

#	ARTICLE	IF	CITATIONS
811	Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response. <i>Cancer Research and Treatment</i> , 2020, 52, 594-603.	1.3	55
812	Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 367-402.	2.3	326
813	Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 750-757.	2.3	86
814	NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 364-376.	2.3	167
815	Survival in Patients With Sentinel Node-Positive Melanoma With Extranodal Extension. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1165-1173.	2.3	3
816	Melanoma sentinel lymph node biopsy and completion lymph node dissection: A regional hospital experience. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2022, 75, 730-736.	0.5	2
817	Severe necrotizing myopathy after COVID-19 vaccine with BNT162b2 and regimen with ipilimumab plus nivolumab in a patient with advanced melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	11
818	Effects of Tumor-Derived Exosome Programmed Death Ligand 1 on Tumor Immunity and Clinical Applications. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 760211.	1.8	9
819	Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma. <i>European Journal of Cancer</i> , 2021, 158, 225-233.	1.3	8
821	A case of laparoscopic partial hepatic S7 resection for postoperative liver metastasis of rectal malignant melanoma. <i>Surgical Case Reports</i> , 2021, 7, 230.	0.2	1
822	High-Dimensional Single-Cell Transcriptomics in Melanoma and Cancer Immunotherapy. <i>Genes</i> , 2021, 12, 1629.	1.0	8
823	Epigenetic Silencing of BMP6 by the SIN3A-HDAC1/2 Repressor Complex Drives Melanoma Metastasis via FAM83G/PAWS1. <i>Molecular Cancer Research</i> , 2022, 20, 217-230.	1.5	3
824	Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition – A Descriptive Observational Retrospective Multicenter Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 765608.	1.3	10
825	Adjuvant systemic treatment for high-risk resected non-cutaneous melanomas: What is the evidence?. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 167, 103503.	2.0	2
827	Évaluation de l'efficacité et de la tolérance de la thérapie combinée par immunothérapie et thérapie ciblée dans le mélanome cutané avancé. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018, 33, 102-115.	0	0
828	Immune checkpoint inhibitors for locally advanced head and neck cancer. <i>Japanese Journal of Head and Neck Cancer</i> , 2018, 44, 258-262.	0.0	0
829	Enjeux et difficultés de la gestion des médicaments oncothérapeutiques non inscrits dans la liste en sus pour un hôpital traitant des cancers. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2018, 202, 1003-1012.	0.0	0
830	Conclusion de la séance d'actualité: « Les coûts des médicaments des cancers ». <i>Bulletin De L'Academie Nationale De Medecine</i> , 2018, 202, 1025-1026.	0.0	0

#	ARTICLE	IF	CITATIONS
832	CongrÃ©s de lâ€™association amÃ©ricaine de recherche contre le cancer â€™ AACR 2018. Oncologie, 2018, 20, 49-70.	0.2	0
833	Progress in adjuvant treatment of melanoma patients. Nowotwory, 2018, 68, 140-145.	0.1	0
834	Melanoma Vaccines. , 2019, , 1-23.		0
835	Evolving Role of the Oncology Nurse in the Care of Patients with Melanoma. , 2019, , 1-27.		1
836	Neoadjuvant Systemic Therapy for High-Risk Melanoma Patients. , 2019, , 1-27.		0
837	Adjuvant Systemic Therapy for High-Risk Melanoma Patients. , 2019, , 1-20.		0
838	Dermatological Complications of Systemic Therapies for Melanoma. , 2019, , 1-22.		0
839	Melanom. , 2019, , 45-134.		0
840	Surgical Management of Distant Melanoma Metastases. , 2019, , 1-44.		0
841	Cutaneous melanoma: Latest developments. Australian Journal of General Practice, 2019, 48, 349-353.	0.3	0
842	Analysis of Programmed Death-Ligand 1 Expression, Stromal Tumor-Infiltrating Lymphocytes, and Mismatch Repair Deficiency in Invasive Micropapillary Carcinoma of the Breast. Journal of Immunotherapy and Precision Oncology, 2019, 2, 130-136.	0.6	1
843	Malignancy, Staging andÂSurgical Management. , 2020, , 77-104.		0
844	Impact of Systemic Anticancer Therapy on Fertility. , 2020, , 67-80.		0
845	Isolated Limb Perfusion and Infusion in theÂManagement of In-Transit Melanoma of theÂExtremities: Modern Data Affecting Practice. , 2020, , 379-394.		0
847	Adjuvant Systemic Therapy for High-Risk Melanoma Patients. , 2020, , 747-766.		0
848	Dermatological Complications of Systemic Therapies for Melanoma. , 2020, , 1337-1358.		0
849	Advanced melanoma in adults: Pembrolizumab as a treatment option. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2020, 66, 100-107.	0.3	0
850	Regional Therapies: Clinically-Apparent Nodal Disease. , 2021, , 161-169.		0

#	ARTICLE	IF	CITATIONS
851	Î2-catenin and PD-L1 expression in mismatch repair deficient endometrial carcinomas. International Journal of Gynecological Cancer, 2020, 30, 993-999.	1.2	6
852	Regional Melanoma Therapy: Positive Sentinel Lymph Node. , 2021, , 149-160.		0
853	Adjuvant nivolumab plus ipilimumab for resected stage IV melanoma. Lancet, The, 2020, 395, 1524-1525.	6.3	0
855	Skin melanoma. State of the problem. Review. Russian Journal of Oncology, 2019, 24, 113-120.	0.1	0
856	Tratamiento adyuvante de melanoma cutáneo : indicaciones y alternativas.. Revista Colombiana De Hematología Y Oncología, 2020, 7, 56-63.	0.0	0
857	Overcoming Cancer Tolerance with Immune Checkpoint Blockade. , 2021, , 85-128.		0
858	Effets indésirables rhumatologiques associés aux inhibiteurs de point de contrôle immunitaire: impact sur la survie globale. Revue Du Rhumatisme (Edition Francaise), 2021, 89, 168-168.	0.0	0
859	The (re)discovery of tumor-intrinsic determinants of immune sensitivity by functional genetic screens. Immuno-Oncology Technology, 2021, 11, 100043.	0.2	9
860	Bioinformatic and Machine Learning Applications in Melanoma Risk Assessment and Prognosis: A Literature Review. Genes, 2021, 12, 1751.	1.0	7
861	Sentinel node biopsy in cutaneous melanoma patients with germline CDKN2A mutations. Melanoma Research, 2020, 30, 630-631.	0.6	1
862	Applications of Antibodies in Therapy, Diagnosis, and Science. Learning Materials in Biosciences, 2021, , 129-159.	0.2	0
863	Locally advanced head and neck squamous cell carcinoma and melanoma simultaneously treated with pembrolizumab: an unusual situation. European Journal of Dermatology, 2020, 30, 743-744.	0.3	0
864	Letter Regarding Editorial by Samuel Zagarella. American Journal of Dermatopathology, 2021, 43, 539-541.	0.3	2
865	Sequencing and Combinations of Molecularly Targeted and Immunotherapy for BRAF-Mutant Melanoma. , 2020, , 1215-1241.		0
866	Melanoma Vaccines. , 2020, , 1243-1265.		0
867	CHAPTER 14. Cell and Immune Therapy. RSC Detection Science, 2020, , 303-344.	0.0	0
868	Cutaneous Melanoma – A Review of Systemic Therapies. Acta Dermato-Venereologica, 2020, 100, adv00141.	0.6	7
869	Tumoren der Haut. , 2020, , 899-914.		0

#	ARTICLE	IF	CITATIONS
870	Neue Arzneimittel 2019. , 2020, , 43-150.		2
871	Bioactive Lipid (BAL)-Based Therapeutic Approach to Cancer That Enhances Antitumor Action and Ameliorates Cytokine Release Syndrome of Immune Checkpoint Inhibitors. , 2020, , 207-235.		0
872	Cancer Immunotherapy Confers a Global Benefit. , 2020, , 1-48.		0
873	Adjuvant therapy for melanoma: how to choose?. Lancet Oncology, The, 2020, 21, 319-320.	5.1	2
874	Safety Profile of Immunotherapy Combined With Antiangiogenic Therapy in Patients With Melanoma: Analysis of Three Clinical Studies. Frontiers in Pharmacology, 2021, 12, 747416.	1.6	0
875	Immune-checkpoint inhibitors in renal transplanted patients affected by melanoma: a systematic review. Immunotherapy, 2022, 14, 65-75.	1.0	6
876	Checkpoint Inhibitors in Melanoma Patients with Underlying Autoimmune Disease. Cancer Management and Research, 2021, Volume 13, 8199-8208.	0.9	9
877	Risk factors for immune-related adverse events: what have we learned and what lies ahead?. Biomarker Research, 2021, 9, 79.	2.8	36
878	Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside. Frontiers in Endocrinology, 2021, 12, 764138.	1.5	22
879	Robust immune response stimulated by in situ injection of CpG/Î±OX40/cGAMP in Î±PD-1-resistant malignancy. Cancer Immunology, Immunotherapy, 2022, 71, 1597-1609.	2.0	2
880	Role of debulking surgery in combination with immune therapy: A successfully treated case of locally advanced mucosal melanoma. Molecular and Clinical Oncology, 2021, 16, 2.	0.4	1
881	Risk of colitis in immune checkpoint inhibitors and in chemotherapy/placebo for solid tumors: a systematic review and meta-analysis. Translational Cancer Research, 2020, 9, 4173-4187.	0.4	2
882	Is AJCC 8th Edition useful in qualifying melanoma patients to adjuvant therapy?. Annals of Translational Medicine, 2020, 8, 898-898.	0.7	0
884	Life-threatening polymyositis with spontaneous hematoma induced by nivolumab in a patient with previously resected melanoma. Melanoma Research, 2021, 31, 85-87.	0.6	4
885	Real-accessible novelties in immunotherapy from the perspective of a medical oncologist working in the Czech Republic. Onkologie (Czech Republic), 2020, 14, 199-204.	0.0	0
886	Tratamiento adyuvante en el melanoma. Piel, 2020, 35, 522-525.	0.0	0
888	Immunotherapy. Canadian Family Physician, 2021, 67, 512-515.	0.1	0
890	Prolonged Complete Response of Early Stage Primary Adenocarcinoma of the Lung to Nivolumab Monotherapy. , 2021, 4, .		0

#	ARTICLE	IF	CITATIONS
891	<i>In Situ</i> Visualization of PD-L1-Specific Glycosylation on Tissue Sections. <i>Analytical Chemistry</i> , 2021, 93, 15958-15963.	3.2	18
892	Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies. <i>Current Oncology</i> , 2021, 28, 4894-4928.	0.9	0
893	External validation of the American Joint Committee on Cancer melanoma staging system eighth edition using the surveillance, epidemiology, and end results program. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, , .	0.7	1
895	Clinical Significance of Distant Metastasis-Free Survival (DMFS) in Melanoma: A Narrative Review from Adjuvant Clinical Trials. <i>Journal of Clinical Medicine</i> , 2021, 10, 5475.	1.0	8
896	Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2021, 158, 156-168.	1.3	19
897	Adjuvant Pembrolizumab versus IFN α 2b or Ipilimumab in Resected High-Risk Melanoma. <i>Cancer Discovery</i> , 2022, 12, 644-653.	7.7	32
898	Neoantigen-Reactive T Cells: The Driving Force behind Successful Melanoma Immunotherapy. <i>Cancers</i> , 2021, 13, 6061.	1.7	5
899	Cost-effectiveness of adjuvant systemic therapies for patients with high-risk melanoma in Europe: a model-based economic evaluation. <i>ESMO Open</i> , 2021, 6, 100303.	2.0	7
900	Immunotherapy for Melanoma. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 81-111.	0.8	7
902	Surgical Outcomes of Vaginal or Cervical Melanoma. <i>Frontiers in Surgery</i> , 2021, 8, 771160.	0.6	1
903	Camrelizumab-Related Myocarditis and Myositis With Myasthenia Gravis: A Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2021, 11, 778185.	1.3	10
904	Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer. <i>Cancers</i> , 2022, 14, 294.	1.7	24
905	Utilization and survival benefit of adjuvant immunotherapy in resected high-risk stage II melanoma. <i>Surgery in Practice and Science</i> , 2022, 8, 100056.	0.2	0
906	Nuclear PD-L1 promotes cell cycle progression of BRAF-mutated colorectal cancer by inhibiting THRAP3. <i>Cancer Letters</i> , 2022, 527, 127-139.	3.2	18
907	Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma. <i>ESMO Open</i> , 2022, 7, 100357.	2.0	10
908	Appraisal of International Guidelines for Cutaneous Melanoma Management using the AGREE II assessment tool. <i>JPRAS Open</i> , 2022, 31, 114-122.	0.4	1
909	Fortgeschrittenes malignes Melanom: Kernpunkte der aktualisierten Leitlinie. , 0, , .		0
911	Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti- α PD-1 Therapy. <i>JCO Precision Oncology</i> , 2021, 5, 1821-1829.	1.5	17

#	ARTICLE	IF	CITATIONS
912	Signal pathways of melanoma and targeted therapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 424.	7.1	115
913	Sentinel Lymph Node Biopsy Positivity in Patients With Acral Lentiginous and Other Subtypes of Cutaneous Melanoma. <i>JAMA Dermatology</i> , 2022, 158, 51.	2.0	7
914	Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial. <i>Cancers</i> , 2022, 14, 682.	1.7	6
915	Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?. <i>Journal of Hematology and Oncology</i> , 2022, 15, 6.	6.9	17
916	Adjuvant Nivolumab or Ipilimumab + Nivolumab for Melanoma Determined by Pathological Response to a Single Dose of Neoadjuvant Nivolumab. <i>Annals of Surgical Oncology</i> , 2022, , 1.	0.7	0
917	The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy. <i>BMC Cancer</i> , 2022, 22, 99.	1.1	14
918	International Center-Level Variation in Utilization of Completion Lymph Node Dissection and Adjuvant Systemic Therapy for Sentinel Lymph Node-Positive Melanoma at Major Referral Centers. <i>Annals of Surgery</i> , 2023, 277, e1106-e1115.	2.1	7
919	Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). <i>Annals of Surgical Oncology</i> , 2022, 29, 3694-3708.	0.7	21
921	Cancer outcome research – a European challenge Part II: Opportunities and priorities. <i>Molecular Oncology</i> , 2022, 16, 2300-2311.	2.1	1
922	The Impact of Hyaluronan on Tumor Progression in Cutaneous Melanoma. <i>Frontiers in Oncology</i> , 2021, 11, 811434.	1.3	6
923	Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. <i>Cancer Cell</i> , 2022, 40, 88-102.e7.	7.7	64
924	Cancer cell-expressed BTNL2 facilitates tumour immune escape via engagement with IL-17A-producing $\hat{I}^3\hat{I}^T$ cells. <i>Nature Communications</i> , 2022, 13, 231.	5.8	14
925	Surgery-mediated tumor-promoting effects on the immune microenvironment. <i>Seminars in Cancer Biology</i> , 2022, 86, 408-419.	4.3	29
926	New Therapeutic Approaches for Conjunctival Melanoma – What We Know So Far and Where Therapy Is Potentially Heading: Focus on Lymphatic Vessels and Dendritic Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1478.	1.8	4
927	Inborn Errors of Immunity and Their Phenocopies: CTLA4 and PD-1. <i>Frontiers in Immunology</i> , 2021, 12, 806043.	2.2	7
928	Squamous cell carcinoma of the lung: improving the detection and management of immune-related adverse events. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 203-213.	1.1	4
929	Is the presence of tumor-infiltrating lymphocytes predictive of outcomes in patients with melanoma?. <i>Cancer</i> , 2022, 128, 1418-1428.	2.0	4
930	The Effect of Inflammatory Markers on the Survival of Advanced Gastric Cancer Patients Who Underwent Anti-Programmed Death 1 Therapy. <i>Frontiers in Oncology</i> , 2022, 12, 783197.	1.3	13

#	ARTICLE	IF	CITATIONS
931	Evidence and implementation gaps in management of sentinel node- ⁺ positive melanoma in the United States. <i>Surgery</i> , 2022, 172, 226-233.	1.0	5
932	Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus. <i>European Journal of Cancer</i> , 2022, 163, 79-87.	1.3	17
933	Renin-angiotensin-aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2022, 163, 108-118.	1.3	21
934	Immune checkpoint inhibitors for the treatment of melanoma. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 563-576.	1.4	10
935	Managing Metastatic Melanoma in 2022: A Clinical Review. <i>JCO Oncology Practice</i> , 2022, 18, 335-351.	1.4	91
936	The diagnostic accuracy and clinical impact of FDG-PET/CT follow-up for patients on adjuvant immunotherapy for high-risk malignant melanoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2342-2351.	3.3	6
937	Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy. <i>Immune Network</i> , 2022, 22, e2.	1.6	53
938	Melanoma and Quality of Life. , 2022, , 439-466.		2
939	Identification of tumor antigens for T-cell-mediated cancer immunotherapy. , 2022, , 85-96.		0
940	Neoadjuvant therapy for melanoma: rationale for neoadjuvant therapy and pivotal clinical trials. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210830.	1.4	13
942	25 Years of Adjuvant Therapy in Melanoma: A Perspective on Current Approvals and Insights into Future Directions. <i>Current Oncology Reports</i> , 2022, 24, 533-542.	1.8	3
943	Management of In-Transit Metastases. <i>Current Oncology Reports</i> , 2022, 24, 573.	1.8	0
944	Adjuvant Therapy With PD1/PDL1 Inhibitors for Human Cancers: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2022, 12, 732814.	1.3	1
945	PKC ζ /ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2022, 77, 163-176.	1.8	52
946	TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 833-840.	1.2	6
947	Treat Now or Treat Later: Comparative Effectiveness of Adjuvant Therapy in Resected Stage IIIA Melanoma. <i>Journal of the American College of Surgeons</i> , 2022, 234, 521-528.	0.2	3
948	An Immune-Related Gene Pair Index Predicts Clinical Response and Survival Outcome of Immune Checkpoint Inhibitors in Melanoma. <i>Frontiers in Immunology</i> , 2022, 13, 839901.	2.2	1
949	Patient and treatment characteristics of emergency presentations due to immune-mediated toxicities. <i>European Journal of Cancer</i> , 2022, 164, 62-69.	1.3	4

#	ARTICLE	IF	CITATIONS
950	Treatment of Metastatic Melanoma in the Elderly. <i>Current Oncology Reports</i> , 2022, 24, 825-833.	1.8	5
951	First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 499-514.	1.1	7
953	The Current State of Treatment and Future Directions in Cutaneous Malignant Melanoma. <i>Biomedicines</i> , 2022, 10, 822.	1.4	18
955	Is Timing of Steroid Exposure Prior to Immune Checkpoint Inhibitor Initiation Associated with Treatment Outcomes in Melanoma? A Population-Based Study. <i>Cancers</i> , 2022, 14, 1296.	1.7	8
956	Harmonization of programmed deathâ€”ligand 1 immunohistochemistry and mRNA expression scoring in metastatic melanoma: a multicentre analysis. <i>Histopathology</i> , 2022, 80, 1091-1101.	1.6	6
957	Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study. <i>Cancer Discovery</i> , 2022, 12, 654-669.	7.7	34
958	Risk of Immune-Related Pneumonitis with PD-1/PD-L1 Inhibitors in Different Cancer Types and Treatment Regimens: A Systematic Review and Meta-Analysis of 22 Randomized Controlled Trials. <i>Chemotherapy</i> , 2023, 68, 1-15.	0.8	0
959	Tumour growth rate improves tumour assessment and first-line systemic treatment decision-making for immunotherapy in patients with liver metastatic uveal melanoma. <i>British Journal of Cancer</i> , 2022, 127, 258-267.	2.9	4
961	Follow-up of primary melanoma patients with high risk of recurrence: recommendations based on evidence and consensus. <i>Clinical and Translational Oncology</i> , 2022, , 1.	1.2	2
962	Implications of systemic adjuvant melanoma treatments for U.K. melanoma services: Results of the U.K. Melanoma Adjuvant Pathway Survey. <i>European Journal of Cancer Care</i> , 2022, , e13565.	0.7	0
963	How to overcome tumor resistance to anti-PD-1/PD-L1 therapy by immunotherapy modifying the tumor microenvironment in MSS CRC. <i>Clinical Immunology</i> , 2022, 237, 108962.	1.4	16
964	The Role of NcrNAs to Regulate Immune Checkpoints in Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 853480.	2.2	12
965	Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing. <i>BioDrugs</i> , 2022, 36, 373-380.	2.2	2
966	Prognostic and predictive value of Î²-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2022, 165, 97-112.	1.3	18
967	Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2022, 399, 1718-1729.	6.3	236
968	TET1 mutations as a predictive biomarker for immune checkpoint inhibitors in colon adenocarcinoma. <i>World Journal of Surgical Oncology</i> , 2022, 20, 115.	0.8	1
969	Management of Head and Neck Mucosal Melanoma. <i>Oral and Maxillofacial Surgery Clinics of North America</i> , 2022, 34, 299-314.	0.4	2
970	Triplet Therapy in Melanoma â€” Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies. <i>Current Oncology Reports</i> , 2022, 24, 1071-1079.	1.8	11

#	ARTICLE	IF	CITATIONS
971	Characterization of the treatment-naive immune microenvironment in melanoma with <i>BRAF</i> mutation. , 2022, 10, e004095.		7
972	Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Translational Oncology</i> , 2022, 19, 101383.	1.7	4
973	Safety, efficacy, and tolerability of immune checkpoint inhibitors in the treatment of hepatocellular carcinoma. <i>Surgical Oncology</i> , 2022, 42, 101748.	0.8	2
974	Chronic Kidney Disease in Cancer Survivors. <i>Advances in Chronic Kidney Disease</i> , 2021, 28, 469-476.e1.	0.6	5
975	Adjuvant therapy of malignant melanoma: general and practical experience. <i>Onkologie (Czech)</i> Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 58	0.6	0
976	An RNA-RNA crosstalk network involving HMGB1 and RICTOR facilitates hepatocellular carcinoma tumorigenesis by promoting glutamine metabolism and impedes immunotherapy by PD-L1+ exosomes activity. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 421.	7.1	48
977	Melanoma trials that defined surgical management: Brief overview of current/upcoming adjuvant/neoadjuvant trials. <i>Journal of Surgical Oncology</i> , 2022, 125, 38-45.	0.8	1
978	Immunological responses to adjuvant vaccination with combined CD1c ⁺ myeloid and plasmacytoid dendritic cells in stage III melanoma patients. <i>OncImmunology</i> , 2022, 11, .	2.1	14
979	The foundations of immune checkpoint blockade and the ipilimumab approval decennial. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 509-528.	21.5	201
980	Neoadjuvant immune checkpoint inhibitors in high-risk stage III melanoma. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-11.	1.4	3
981	Immunotherapy Resistance in Glioblastoma. <i>Frontiers in Genetics</i> , 2021, 12, 750675.	1.1	13
982	Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 803410.	2.2	25
983	The Role of Myeloid Cells in Hepatotoxicity Related to Cancer Immunotherapy. <i>Cancers</i> , 2022, 14, 1913.	1.7	7
984	Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 862084.	2.2	18
985	Frailty and checkpoint inhibitor toxicity in older patients with melanoma. <i>Cancer</i> , 2022, 128, 2746-2752.	2.0	12
986	Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events. <i>JAMA Network Open</i> , 2022, 5, e227722.	2.8	25
987	In Vivo miRNA Decoy Screen Reveals miR-124a as a Suppressor of Melanoma Metastasis. <i>Frontiers in Oncology</i> , 2022, 12, 852952.	1.3	2
1059	Incidence of hepatotoxicity associated with addition of immune checkpoint blockade to systemic solid tumor therapy: a meta-analysis of phase 3 randomized controlled trials. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2837-2848.	2.0	5

#	ARTICLE	IF	CITATIONS
1060	Optimal systemic therapy for high-risk resectable melanoma. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 431-439.	12.5	12
1062	Lâ€™immunothÃ©rapie. <i>Canadian Family Physician</i> , 2021, 67, e174-e177.	0.1	1
1064	Melanoma: An immunotherapyÂJourney from bench to bedside. <i>Cancer Treatment and Research</i> , 2022, 183, 49-89.	0.2	0
1066	Translating Molecules into Imagingâ€”The Development of New PET Tracers for Patients with Melanoma. <i>Diagnostics</i> , 2022, 12, 1116.	1.3	7
1067	Cancer-specific mortality in patients with non-metastatic renal cell carcinoma who have undergone a nephrectomy and are eligible for adjuvant pembrolizumab. <i>Seminars in Oncology</i> , 2022, .	0.8	2
1068	Functionalization of Nanomaterials for Skin Cancer Theranostics. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, 887548.	2.0	1
1069	The Use and Technique of Sentinel Node Biopsy for Skin Cancer. <i>Plastic and Reconstructive Surgery</i> , 2022, 149, 995e-1008e.	0.7	0
1070	Evaluation of the Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International, Multicenter Study. <i>Annals of Surgical Oncology</i> , 2022, 29, 5937-5945.	0.7	4
1072	Incidence of fatigue associated with immune checkpoint inhibitors in patients with cancer: a meta-analysis. <i>ESMO Open</i> , 2022, 7, 100474.	2.0	3
1073	Clinically Significant Risk Thresholds in the Management of Primary Cutaneous Melanoma: A Survey of Melanoma Experts. <i>Annals of Surgical Oncology</i> , 2022, .	0.7	2
1074	Risk factors for pneumonitis in advanced extrapulmonary cancer patients treated with immune checkpoint inhibitors. <i>BMC Cancer</i> , 2022, 22, 551.	1.1	4
1075	Re-introduction of T-VEC Monotherapy in Recurrent Melanoma is Effective. <i>Journal of Immunotherapy</i> , 2022, Publish Ahead of Print, .	1.2	1
1076	Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome. , 2022, 10, e004329.		15
1077	Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study. <i>Journal of Investigative Dermatology</i> , 2022, 142, 2896-2908.e4.	0.3	9
1078	Monitoring and Management of the Patient with Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis: Current Perspectives. <i>Journal of Inflammation Research</i> , 0, Volume 15, 3105-3118.	1.6	6
1079	Double Trouble: Immunotherapy Doublets in Melanomaâ€”Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 745-766.	1.8	6
1080	Immunogenicity of COVID-19 Vaccination in Melanoma Patients under Immune Checkpoint Blockade. <i>Oncology</i> , 2022, 100, 392-398.	0.9	5
1081	Classification of <sc>PDâ€1</sc> expression in various cancers and macrophages based on immunohistocytological analysis. <i>Cancer Science</i> , 2022, 113, 3255-3266.	1.7	8

#	ARTICLE	IF	CITATIONS
1082	European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022. <i>European Journal of Cancer</i> , 2022, 170, 256-284.	1.3	92
1083	Adjuvant nodal field radiation in resected Stage <sc>III</sc> melanoma: A single-centre retrospective study in Christchurch, New Zealand. <i>Journal of Medical Imaging and Radiation Oncology</i> , 0, .	0.9	0
1084	Neoadjuvant immunotherapy in gastrointestinal cancers – The new standard of care?. <i>Seminars in Cancer Biology</i> , 2022, 86, 834-850.	4.3	12
1085	Progress in the Treatment of Advanced Melanoma. <i>Advances in Clinical Medicine</i> , 2022, 12, 5256-5262.	0.0	0
1088	Treatment Approaches for Melanomas That Relapse After Adjuvant or Neoadjuvant Therapy. <i>Current Oncology Reports</i> , 2022, 24, 1273-1280.	1.8	5
1089	Adjuvant Anti-PD-1 Antibody Therapy for Advanced Melanoma: A Multicentre Study of 78 Japanese Cases. <i>Acta Dermato-Venereologica</i> , 0, 102, adv00756.	0.6	8
1090	Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. <i>Journal of Clinical Oncology</i> , 2022, 40, 3741-3749.	0.8	33
1091	The Treatment of Advanced Melanoma: Therapeutic Update. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6388.	1.8	41
1092	Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy. , 2022, 10, e004771.		16
1093	Population-based assessment of sentinel lymph node biopsy in the management of cutaneous melanoma. <i>Canadian Journal of Surgery</i> , 2022, 65, E394-E403.	0.5	4
1094	Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study. <i>Annals of Oncology</i> , 2022, 33, 968-980.	0.6	22
1095	Conversion surgery for microsatellite instability-high gastric cancer with a complete pathological response to pembrolizumab: a case report. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	3
1096	Cancer treatment and survivorship statistics, 2022. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 409-436.	157.7	897
1097	De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer. <i>European Journal of Cancer</i> , 2022, 171, 55-63.	1.3	8
1098	Progress in advanced nanotherapeutics for enhanced photodynamic immunotherapy of tumor. <i>Theranostics</i> , 2022, 12, 5272-5298.	4.6	21
1099	Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-Transit Melanoma Metastases. <i>Annals of Surgical Oncology</i> , 2022, 29, 7019-7028.	0.7	3
1100	Lack of Efficacy of Immune Checkpoint Inhibitors in Cancer Patients Older Than 75?. <i>Journal of Immunotherapy</i> , 0, Publish Ahead of Print, .	1.2	0
1101	Charting roadmaps towards novel and safe synergistic immunotherapy combinations. <i>Nature Cancer</i> , 2022, 3, 665-680.	5.7	18

#	ARTICLE	IF	CITATIONS
1102	Predictors of Sentinel Lymph Node Metastasis in Patients with Thin Melanoma: An International Multi-institutional Collaboration. <i>Annals of Surgical Oncology</i> , 2022, 29, 7010-7017.	0.7	3
1103	Proliferation Marker Ki67 as a Stratification Index of Adjuvant Chemotherapy for Resectable Mucosal Melanoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1104	Immune checkpoint inhibitors and kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2022, 31, 449-455.	1.0	3
1105	Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	9
1106	Evaluating HEMopatch [®] in Reducing Seroma-Related Complications following Axillary Lymph Node Dissection: A Pilot Study (HEIDI). <i>Breast Care</i> , 2022, 17, 567-572.	0.8	2
1107	Toripalimab (anti-PD-1) versus high-dose interferon- γ 2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial. <i>Annals of Oncology</i> , 2022, 33, 1061-1070.	0.6	19
1108	Risk of Rash in PD-1 or PD-L1-Related Cancer Clinical Trials: A Systematic Review and Meta-Analysis. <i>Journal of Oncology</i> , 2022, 2022, 1-27.	0.6	5
1109	Immune suppression in the tumor-draining lymph node corresponds with distant disease recurrence in patients with melanoma. <i>Cancer Cell</i> , 2022, 40, 798-799.	7.7	16
1110	Objective assessment of tumor infiltrating lymphocytes as a prognostic marker in melanoma using machine learning algorithms. <i>EBioMedicine</i> , 2022, 82, 104143.	2.7	12
1111	Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination. <i>Journal of Clinical Oncology</i> , 2023, 41, 75-85.	0.8	42
1112	Real-world safety and effectiveness of pembrolizumab in Japanese patients with radically unresectable melanoma: An all-case postmarketing surveillance in Japan. <i>Journal of Dermatology</i> , 2022, 49, 1096-1105.	0.6	4
1113	Diagnóstico y tratamiento multidisciplinario de melanoma temprano y localmente avanzado. Consenso de expertos. Asociación Colombiana de Hemato-Oncología (ACHO).. <i>Revista Colombiana De Cancerología</i> , 2021, 25, 196-205.	0.0	0
1114	Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 4373.	1.0	1
1115	Fertility preservation for patients with melanoma. <i>Melanoma Research</i> , 0, Publish Ahead of Print, .	0.6	2
1116	Clinical Outcomes and Risk Stratification of Early-Stage Melanoma Micrometastases From an International Multicenter Study: Implications for the Management of American Joint Committee on Cancer IIIA Disease. <i>Journal of Clinical Oncology</i> , 2022, 40, 3940-3951.	0.8	13
1117	Distinct antibody clones detect PD-1 checkpoint expression and block PD-L1 interactions on live murine melanoma cells. <i>Scientific Reports</i> , 2022, 12, .	1.6	7
1118	Proton Therapy Outcomes for Head and Neck Cutaneous Melanoma: Proton Collaborative Group Analysis. <i>International Journal of Particle Therapy</i> , 2022, 9, 40-48.	0.9	0
1119	Prognostic value of neutrophil-lymphocyte ratio and lactate dehydrogenase in melanoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Medicine (United Tj ETQq1 1 06784314 rgBT /Over</i>		

#	ARTICLE	IF	CITATIONS
1120	PD-L1+ neutrophils as novel biomarkers for stage IV melanoma patients treated with nivolumab. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1121	Treatment of Metastatic Melanoma at First Diagnosis: Review of the Literature. <i>Life</i> , 2022, 12, 1302.	1.1	5
1122	Predicting Regional Lymph Node Recurrence in the Modern Age of Tumor-Positive Sentinel Node Melanoma: The Role of the First Postoperative Ultrasound. <i>Annals of Surgical Oncology</i> , 2022, 29, 8469-8477.	0.7	2
1123	Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial. <i>BMC Cancer</i> , 2022, 22, .	1.1	12
1124	Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria. <i>European Journal of Cancer</i> , 2022, 173, 285-296.	1.3	16
1125	Reporting of melanoma cell densities in the sentinel node refines outcome prediction. <i>European Journal of Cancer</i> , 2022, 174, 121-130.	1.3	2
1126	Vulvovaginal melanoma. , 2023, , 279-304.		0
1127	Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-III A non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 1274-1286.	5.1	202
1128	Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study. <i>European Journal of Cancer</i> , 2022, 175, 224-235.	1.3	13
1129	Cumulative incidence and risk factors of brain metastasis for acral and mucosal melanoma patients with stages I-III. <i>European Journal of Cancer</i> , 2022, 175, 196-203.	1.3	1
1130	Diagnostic Applications of Nuclear Medicine: Malignant Melanoma. , 2022, , 1235-1269.		0
1131	Survival of patients with stage IIIC and IIID melanomas with nodal metastases in the light of new therapies. <i>Postepy Dermatologii i Alergologii</i> , 2022, 39, 1141-1150.	0.4	1
1132	Cambios histopatológicos secundarios a terapia diana en melanoma. <i>Actas Dermo-sifiliográficas</i> , 2022, 114, 75-75.	0.2	0
1133	Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites. , 2022, 10, e004884.		15
1134	Disease Recurrence during Adjuvant Immune Checkpoint Inhibitor Treatment in Metastatic Melanoma: Clinical, Laboratory, and Radiological Characteristics in Patients from a Single Tertiary Referral Center. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10723.	1.8	3
1135	Immune checkpoint inhibitors – the revolutionary cancer immunotherapy comes with a cardiotoxic price. <i>Trends in Cardiovascular Medicine</i> , 2024, 34, 71-77.	2.3	6
1136	Intratumoral CD73: An immune checkpoint shaping an inhibitory tumor microenvironment and implicating poor prognosis in Chinese melanoma cohorts. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
1137	The extracellular matrix alteration, implication in modulation of drug resistance mechanism: friends or foes?. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	31

#	ARTICLE	IF	CITATIONS
1138	Low-dose PD-1 inhibitor combined with lenvatinib for preemptive treatment of recurrence after liver transplantation for hepatocellular carcinoma: Case report and literature review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1139	What Surgeons Need to Know About Gene Therapy for Cancer. <i>Advances in Surgery</i> , 2022, 56, 151-168.	0.6	1
1140	Is Melanoma Progression Affected by Thyroid Diseases?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10036.	1.8	3
1141	Long response duration to pembrolizumab in metastatic, castration-resistant prostate cancer with microsatellite instability-high and neuroendocrine differentiation: A case report. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
1143	Implementation of melanoma guidelines in the multidisciplinary setting: A qualitative analysis. <i>American Journal of Surgery</i> , 2023, 225, 335-340.	0.9	2
1144	Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	5
1145	Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915). <i>Journal of Clinical Oncology</i> , 2023, 41, 517-527.	0.8	59
1146	Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma. , 2022, 1, .		29
1147	Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial. <i>Lancet, The</i> , 2022, 400, 1117-1129.	6.3	45
1148	Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study. <i>European Journal of Cancer</i> , 2022, 176, 207-217.	1.3	7
1149	Prognostic value of cuproptosis-related genes signature and its impact on the reshaped immune microenvironment of glioma. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
1151	Systemic adjuvant therapy for high-risk cutaneous melanoma. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211340.	1.4	7
1152	Targeted Therapy and Immunotherapy in Melanoma. <i>Dermatologic Clinics</i> , 2023, 41, 65-77.	1.0	14
1153	Current understanding of epigenetics role in melanoma treatment and resistance. <i>Cancer Cell International</i> , 2022, 22, .	1.8	15
1154	Update on immune checkpoint therapy for melanoma. <i>Dermatological Reviews</i> , 0, , .	0.3	0
1155	Melanoma lymph node metastases “moving beyond quantity in clinical trial design and contemporary practice. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
1156	Novel Biomarkers and Therapeutic Targets for Melanoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11656.	1.8	3
1157	Intermediate-thickness melanoma: A population-based study of surgical quality metrics. <i>Surgery</i> , 2023, 173, 626-632.	1.0	1

#	ARTICLE	IF	CITATIONS
1160	Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients. <i>Current Oncology</i> , 2022, 29, 7953-7963.	0.9	10
1162	Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	15
1163	Radiomics: A review of current applications and possibilities in the assessment of tumor microenvironment. <i>Diagnostic and Interventional Imaging</i> , 2023, 104, 113-122.	1.8	15
1164	You're Cured Till You're Not: Should Disease-Free Survival Be Used as a Regulatory or Clinical End Point for Adjuvant Therapy of Cancer?. <i>Journal of Clinical Oncology</i> , 2022, 40, 4044-4047.	0.8	5
1165	Neoadjuvant relatlimab and nivolumab in resectable melanoma. <i>Nature</i> , 2022, 611, 155-160.	13.7	114
1166	Selection of a <sc>PD</sc>-1 blocking antibody from a novel fully human phage display library. <i>Protein Science</i> , 2022, 31, .	3.1	7
1167	Prognosis prediction and tumor immune microenvironment characterization based on tryptophan metabolism-related genes signature in brain glioma. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
1169	The end of wide local excision (WLE) margins for melanoma ?. <i>European Journal of Cancer</i> , 2023, 178, 82-87.	1.3	3
1170	Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 1378-1388.	5.1	64
1171	Supervised ML for Identifying Biomarkers Driving the Response to ICBs in Melanoma patients. , 2022, , .		0
1172	Efficacy and safety of adjuvant therapy with PD-1/PD-L1 inhibitors in cancer. <i>Experimental and Therapeutic Medicine</i> , 2022, 24, .	0.8	1
1173	Prognostic significance of age on superficial spreading melanoma after resection: lessons from <sc>SEER</sc> database involving 12%536 patients. <i>ANZ Journal of Surgery</i> , 0, , .	0.3	0
1174	Real-world clinical outcomes of patients with stage IIB or IIC cutaneous melanoma treated at US community oncology clinics. <i>Future Oncology</i> , 2022, 18, 3755-3767.	1.1	1
1175	Application of Electronic Health Record Text Mining: Real-World Tolerability, Safety, and Efficacy of Adjuvant Melanoma Treatments. <i>Cancers</i> , 2022, 14, 5426.	1.7	3
1177	Best practices in surgical and nonsurgical management of head and neck Merkel cell carcinoma: An update. <i>Molecular Carcinogenesis</i> , 2023, 62, 101-112.	1.3	4
1178	Serine and glycine metabolism-related gene expression signature stratifies immune profiles of brain gliomas, and predicts prognosis and responses to immunotherapy. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
1179	Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
1180	Deaths and adverse events from adjuvant therapy with immune checkpoint inhibitors in solid malignant tumors: A systematic review and network meta-analysis. , 2022, 1, 293-304.		0

#	ARTICLE	IF	CITATIONS
1181	Completion Lymph Node Dissection for Melanoma Before and After the Multicenter Selective Lymphadenectomy Trial-II in the United States. <i>Annals of Surgical Oncology</i> , 2023, 30, 1184-1193.	0.7	4
1182	Purine metabolism-related gene expression signature predicts survival outcome and indicates immune microenvironment profile of gliomas. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
1184	Tumoren im Kopf-Hals-Bereich. , 2023, , 585-626.		0
1185	Successful Steroid Treatment of Pembrolizumab-induced Agranulocytosis That Developed after Splenectomy in a Patient with Non-small-cell Lung Cancer. <i>Internal Medicine</i> , 2023, 62, 2113-2121.	0.3	2
1186	Patient Preferences and Satisfaction With Decisions in Stage-III Melanoma: A Mixed Methods Study. <i>Journal of Surgical Research</i> , 2023, 283, 485-493.	0.8	0
1187	The Use of Immunotherapy in Cancer Patients with Autoimmune Diseases. , 2023, , 267-286.		0
1188	Durable response to the combination of pembrolizumab and nab-paclitaxel in a metastatic extrahepatic cholangiocarcinoma: A case report and literature review. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
1189	The Flip of the Coin of Personalized Cancer Immunotherapy: A Focused Review on Rare Immune Checkpoint Related Adverse Effects. , 0, , .		0
1190	Photodynamic Opening of the Blood-Brain Barrier and the Meningeal Lymphatic System: The New Niche in Immunotherapy for Brain Tumors. <i>Pharmaceutics</i> , 2022, 14, 2612.	2.0	12
1191	Design and reporting of phase III oncology trials with prospective biomarker validation. <i>Journal of the National Cancer Institute</i> , 0, , .	3.0	1
1192	Risk Stratification of Sentinel Node Metastasis Disease Burden and Phenotype in Stage III Melanoma Patients. <i>Annals of Surgical Oncology</i> , 0, , .	0.7	2
1193	Incidence rate and treatment strategy of immune checkpoint inhibitor mediated hepatotoxicity: A systematic review. , 2023, 1, 46-55.		1
1194	Successful Targeting of CTLA-4 in a Melanoma Clinical Case: A Long-Term "One Stop Therapeutic Shop" OncoTargets and Therapy, 0, Volume 15, 1409-1415.	1.0	2
1195	Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma. , 2022, 10, e005684.		3
1196	Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma. <i>JAMA Oncology</i> , 2023, 9, 251.	3.4	3
1197	Reply to A. Mangla and E. Hindi. <i>Journal of Clinical Oncology</i> , 0, , .	0.8	0
1198	Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15720.	1.8	13
1199	First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti-PD-L1 Antibody ZKAB001. <i>Clinical Cancer Research</i> , 2023, 29, 764-774.	3.2	2

#	ARTICLE	IF	CITATIONS
1200	Immune Checkpoint Inhibitor Therapy in Oncology. <i>JACC: CardioOncology</i> , 2022, 4, 579-597.	1.7	25
1201	Practice patterns for positive sentinel lymph node in head and neck melanoma. <i>Head and Neck</i> , 0, , .	0.9	0
1202	Recurrence Patterns for Regionally Metastatic Melanoma Treated in the Era of Adjuvant Therapy: A Systematic Review and Meta-Analysis. <i>Annals of Surgical Oncology</i> , 0, , .	0.7	0
1203	The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	4
1204	Discovery and Validation of a SIT1-Related Prognostic Signature Associated with Immune Infiltration in Cutaneous Melanoma. <i>Journal of Personalized Medicine</i> , 2023, 13, 13.	1.1	0
1205	Dissecting the Need for Adjuvant Therapy in Patients With Early-Stage Melanoma With Micrometastases. <i>Journal of Clinical Oncology</i> , 2023, 41, 1324-1325.	0.8	2
1206	WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanoma. <i>Cellular Oncology (Dordrecht)</i> , 2023, 46, 391-407.	2.1	3
1207	Melanoma Treatments and Mortality Rate Trends in the US, 1975 to 2019. <i>JAMA Network Open</i> , 2022, 5, e2245269.	2.8	19
1208	SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry. <i>Clinical and Translational Oncology</i> , 0, , .	1.2	0
1209	Assembly of Nanocatalyst As a Noninvasive Tool for Breast Cancer Diagnosis and Immunotherapy Surveillance Designed by Visually Tracking Tumor-Derived Exosomal PD-L1. , 0, , 282-290.		0
1210	Bispecific Aptamer-Based Recognition-then-Conjugation Strategy for PD1/PDL1 Axis Blockade and Enhanced Immunotherapy. <i>ACS Nano</i> , 2022, 16, 21129-21138.	7.3	19
1211	Real-world outcomes using anti-PD-1 antibodies and BRAF+MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2023, 37, 894-906.	1.3	11
1212	Multiple primary malignant neoplasm: Case report and comprehensive literature review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1213	Quality of life and mental health in real-world patients with resected stage III/IV melanoma receiving adjuvant immunotherapy. <i>Acta Oncologica</i> , 2023, 62, 62-69.	0.8	5
1214	Genome-wide DNA methylation profile analysis identifies an individualized predictive signature for melanoma immune response. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 343-356.	1.2	2
1215	Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis. <i>Cancers</i> , 2023, 15, 409.	1.7	3
1216	Neoadjuvant treatment for stage III and IV cutaneous melanoma. <i>The Cochrane Library</i> , 2023, 2023, .	1.5	1
1218	Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	13

#	ARTICLE	IF	CITATIONS
1219	Increasing cure rates of solid tumors by immune checkpoint inhibitors. <i>Experimental Hematology and Oncology</i> , 2023, 12, .	2.0	17
1220	Cutaneous Melanoma in Children. , 2023, , 1-12.		0
1221	Strahlentherapie und Immuntherapie. <i>Springer Reference Medizin</i> , 2023, , 1-20.	0.0	0
1222	An enhanced genetic mutation-based model for predicting the efficacy of immune checkpoint inhibitors in patients with melanoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1223	PPP2R2D Suppresses Effector T Cell Exhaustion and Regulatory T Cell Expansion and Inhibits Tumor Growth in Melanoma. <i>Journal of Immunology</i> , 2022, 209, 621-628.	0.4	1
1224	Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP). <i>European Journal of Cancer</i> , 2023, 182, 155-162.	1.3	9
1225	Dietary Considerations for Inflammatory Bowel Disease Are Useful for Treatment of Checkpoint Inhibitor-Induced Colitis. <i>Cancers</i> , 2023, 15, 84.	1.7	1
1226	Targeting Notch-Driven Cytokine Secretion: Novel Therapies for Triple Negative Breast Cancer. <i>DNA and Cell Biology</i> , 2023, 42, 73-81.	0.9	2
1227	Adjuvant Anti-PD-1 Immunotherapy versus Conventional Therapy for Stage III Melanoma: A Real-World Retrospective Cohort Study. <i>Pharmaceuticals</i> , 2023, 16, 41.	1.7	1
1228	Alternatives and reduced need for sentinel lymph node biopsy (SLNB) staging for melanoma. <i>European Journal of Cancer</i> , 2023, 182, 163-169.	1.3	6
1229	C-Reactive Protein and Lymphocyte-to-Monocyte Ratio Predict Recurrence in Stage III Melanoma Patients with Microscopic Sentinel Lymph Node Metastasis. <i>Cancers</i> , 2023, 15, 702.	1.7	1
1230	Surgery, adjuvant immunotherapy plus chemotherapy and radiotherapy for primary malignant melanoma of the parotid gland (PGMM): A case report. <i>Open Life Sciences</i> , 2023, 18, .	0.6	0
1231	Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials. <i>Annals of Oncology</i> , 2023, 34, 420-430.	0.6	25
1232	Tumor immunology. , 2023, , 245-452.		0
1233	Preoperative Plasma miRNA Levels Predict Prognosis in Early-stage Malignant Melanoma. <i>Anticancer Research</i> , 2023, 43, 695-706.	0.5	0
1234	Adjuvant Systemic Therapy for High-Risk Melanoma. <i>Annals of Surgical Oncology</i> , 0, , .	0.7	1
1235	Mechanisms driving the immunoregulatory function of cancer cells. <i>Nature Reviews Cancer</i> , 2023, 23, 193-215.	12.8	40
1236	An <i>in silico</i> model to study the impact of carbonic anhydrase IX expression on tumour growth and anti-PD-1 therapy. <i>Journal of the Royal Society Interface</i> , 2023, 20, .	1.5	2

#	ARTICLE	IF	CITATIONS
1237	Immunotherapy for older patients with cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2023, 17, 37-46.	0.5	2
1238	Comparison of efficacy and tolerability of adjuvant therapy for resected high-risk stage III-IV cutaneous melanoma: a systemic review and Bayesian network meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592211489.	1.4	2
1239	Optimization of cancer immunotherapy on the basis of programmed death ligand-1 distribution and function. <i>British Journal of Pharmacology</i> , 2024, 181, 257-272.	2.7	4
1240	Neoadjuvant Strategies for Esophageal Cancer. <i>Thoracic Surgery Clinics</i> , 2023, 33, 197-208.	0.4	1
1241	Adjuvant therapy following curative treatments for hepatocellular carcinoma: current dilemmas and prospects. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
1242	Melanome der Haut und Schleimhaut. , 2022, , 205-236.		0
1243	Common toxicities associated with immune checkpoint inhibitors and targeted therapy in the treatment of melanoma: A systematic scoping review. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 183, 103919.	2.0	3
1244	Immunotherapy for Cutaneous Melanoma. , 2023, , 1-35.		0
1245	Reducing workload in malignant melanoma sentinel node examination: a national study of pathology reports from 507 melanoma patients. <i>Journal of Clinical Pathology</i> , 0, , jcp-2022-208743.	1.0	0
1246	Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy. <i>Oncologist</i> , 2023, 28, 351-357.	1.9	5
1247	Cancer Treatment Patterns and Factors Affecting Receipt of Treatment in Older Adults: Results from the ASPREE Cancer Treatment Substudy (ACTS). <i>Cancers</i> , 2023, 15, 1017.	1.7	1
1248	Read the clonotype: Next-generation sequencing-based lymphocyte clonality analysis and perspectives for application in pathology. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
1249	Immunotherapy in Melanoma: Recent Advances and Future Directions. <i>Cancers</i> , 2023, 15, 1106.	1.7	39
1250	Revisiting the Role of the CXCL13/CXCR5-Associated Immune Axis in Melanoma: Potential Implications for Anti-PD-1-Related Biomarker Research. <i>Life</i> , 2023, 13, 553.	1.1	2
1251	Current Controversies in Melanoma Treatment. <i>Plastic and Reconstructive Surgery</i> , 2023, 151, 495e-505e.	0.7	1
1252	⁺ sinus macrophages in regional lymph nodes do not predict mismatch repair status of patients with colorectal cancer. <i>Cancer Medicine</i> , 2023, 12, 10199-10211.	1.3	5
1253	Adjuvant treatment of in-transit melanoma: Narrowing the knowledge gap left by clinical trials. <i>International Journal of Cancer</i> , 0, , .	2.3	0
1254	Immunotherapy in Melanoma: Highlights for the General Practitioner. <i>Praxis</i> , 2023, 112, 135-142.	0.2	1

#	ARTICLE	IF	CITATIONS
1255	Neoadjuvant "Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. New England Journal of Medicine, 2023, 388, 813-823.	13.9	184
1256	A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma. Cancer Immunology, Immunotherapy, 2023, 72, 2267-2282.	2.0	3
1257	Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy. , 2023, 11, e006629.		2
1258	IFN γ score-based neoadjuvant immunotherapy for stage III melanoma. Journal of Experimental Medicine, 2023, 220, .	4.2	0
1259	Description of supportive care and feasibility of physical exercise program to improve quality of life in advanced melanoma patients. Melanoma Research, 2023, 33, 230-238.	0.6	0
1260	Does Stage Migration Occur as a Consequence of Omitting Completion Lymph Node Dissection for Melanoma?. Annals of Surgical Oncology, 0, , .	0.7	0
1261	Immune Checkpoint Inhibitor Associated Myocarditis and Cardiomyopathy: A Translational Review. Biology, 2023, 12, 472.	1.3	2
1262	Ageing microenvironment and antitumor immunity for geriatric oncology: the landscape and future implications. Journal of Hematology and Oncology, 2023, 16, .	6.9	5
1263	Immune checkpoint inhibitor-related thyroid dysfunction. Annales D'Endocrinologie, 2023, 84, 346-350.	0.6	2
1264	Role of the Microbiome in Immunotherapy of Melanoma. Cancer Journal (Sudbury, Mass), 2023, 29, 70-74.	1.0	1
1265	The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A real-world, multicenter, retrospective study. Cancer, 2023, 129, 1885-1894.	2.0	2
1266	Adjuvant radiotherapy after salvage surgery for melanoma recurrence in a node field following a previous lymph node dissection. Journal of Surgical Oncology, 2023, 128, 97-104.	0.8	0
1267	Trends and patterns of care of sentinel node biopsy in cutaneous melanoma: a population-based study in Queensland. ANZ Journal of Surgery, 0, , .	0.3	2
1268	Long-term outcomes of stage IIB-IV melanoma patients: nationwide data from Norway. Future Oncology, 2023, 19, 205-215.	1.1	0
1269	Oncological Outcome After Lymph Node Dissection for Cutaneous Squamous Cell Carcinoma. Annals of Surgical Oncology, 0, , .	0.7	0
1270	Adjuvant dabrafenib and trametinib for patients with resected BRAF-mutated melanoma: DESCRIBE-AD real-world retrospective observational study. Melanoma Research, 2023, 33, 388-397.	0.6	2
1271	Melanom. JDDG - Journal of the German Society of Dermatology, 2023, 21, 343-347.	0.4	1
1273	Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology. , 2023, 11, e006398.		22

#	ARTICLE	IF	CITATIONS
1274	How have immune checkpoint inhibitors transformed melanoma treatment?. Trends in Urology & Men's Health, 2023, 14, 26-30.	0.2	0
1275	Avelumab for the treatment of locally advanced or metastatic Merkel cell carcinoma—A multicenter real-world experience in Israel. Cancer Medicine, 2023, 12, 12065-12070.	1.3	5
1276	DDX39B facilitates the malignant progression of hepatocellular carcinoma via activation of SREBP1-mediated de novo lipid synthesis. Cellular Oncology (Dordrecht), 2023, 46, 1235-1252.	2.1	3
1277	Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238. Clinical Cancer Research, 2023, 29, 3352-3361.	3.2	19
1278	Mutations Status of NOTCH Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colorectal Cancer. Journal of Inflammation Research, 0, Volume 16, 1693-1709.	1.6	1
1279	Melanom. JDDG - Journal of the German Society of Dermatology, 2023, 21, 343-348.	0.4	3
1280	Improving Selection for Sentinel Lymph Node Biopsy Among Patients With Melanoma. JAMA Network Open, 2023, 6, e236356.	2.8	3
1281	Clinical and molecular overview of immunotherapeutic approaches for malignant skin melanoma: Past, present and future. Critical Reviews in Oncology/Hematology, 2023, 186, 103988.	2.0	2
1290	Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma. Nature Reviews Clinical Oncology, 2023, 20, 408-422.	12.5	9
1306	Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors. International Journal of Clinical Oncology, 2023, 28, 941-955.	1.0	2
1316	Neoadjuvant immunotherapy for melanoma is now ready for clinical practice. Nature Medicine, 2023, 29, 1310-1312.	15.2	14
1329	Malignant Melanocytic Tumors: Melanoma. , 2023, , 351-392.		0
1335	Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges. Nature Reviews Clinical Oncology, 2023, 20, 664-677.	12.5	17
1336	Akkermansia muciniphila: a potential booster to improve the effectiveness of cancer immunotherapy. Journal of Cancer Research and Clinical Oncology, 2023, 149, 13477-13494.	1.2	2
1348	Nanoprobe-based molecular imaging for tumor stratification. Chemical Society Reviews, 2023, 52, 6447-6496.	18.7	7
1366	Immunotherapy for Melanoma. , 2023, , 1693-1712.		0
1388	Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. Nature Reviews Immunology, 0, , .	10.6	2
1397	Sentinel lymph nodes in melanoma: necessary as ever for optimal treatment. Clinical and Experimental Metastasis, 0, , .	1.7	0

#	ARTICLE	IF	CITATIONS
1399	Perioperative immunotherapy for resectable non-small-cell lung cancer. , 2024, 3, .		0
1421	Tumoren der Haut. , 2024, , 945-962.		0
1422	è,çç«̄é»‘è%²çç~çš,,èŠæ-â’Ææ²»ç—è¿å±•. Journal of Zhejiang University: Science B, 2024, 25, 106-122.	1.3	0